<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">VET</journal-id>
<journal-id journal-id-type="hwp">spvet</journal-id>
<journal-id journal-id-type="nlm-ta">Vet Pathol</journal-id>
<journal-title>Veterinary Pathology</journal-title>
<issn pub-type="ppub">0300-9858</issn>
<issn pub-type="epub">1544-4221</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300985811430962</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300985811430962</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Overviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Morphologic Manifestations of Gene-Specific Molecular Alterations (“Genetic Addictions”) in Mouse Models of Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Couto</surname>
<given-names>S. S.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300985811430962">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bolon</surname>
<given-names>B.</given-names>
</name>
<xref ref-type="aff" rid="aff2-0300985811430962">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cardiff</surname>
<given-names>R. D.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300985811430962">1</xref>
<xref ref-type="corresp" rid="corresp1-0300985811430962"/>
</contrib>
</contrib-group>
<aff id="aff1-0300985811430962">
<label>1</label>University of California–Davis, Center for Comparative Medicine, Davis, CA, USA</aff>
<aff id="aff2-0300985811430962">
<label>2</label>The Ohio State University, Columbus, OH, USA</aff>
<author-notes>
<corresp id="corresp1-0300985811430962">Robert D. Cardiff, University of California, Davis, Center for Comparative Medicine Department of Pathology.  Email: <email>rdcardiff@ucdavis.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>49</volume>
<issue>1</issue>
<fpage>116</fpage>
<lpage>129</lpage>
<permissions>
<copyright-statement>© American College of Veterinary Pathologists 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">American College of Veterinary Pathologists</copyright-holder>
</permissions>
<abstract>
<p>Neoplasia in both animals and humans results in part from lasting activation of tumor-promoting genes (“oncogenes”) or diminished function of genes responsible for preventing neoplastic induction (“tumor suppressor genes”). The concept of “genetic addiction” has emerged to indicate that neoplastic cells cannot maintain a malignant phenotype without sustained genotypic abnormalities related to aberrant activity of oncogene(s) and/or inactivity of tumor suppressor gene(s). Interestingly, some genetic abnormalities reliably produce distinct morphologic patterns that can be used as structural signatures indicating the presence of a specific molecular alteration. Examples of such consistent genetic/microanatomic pairings have been identified for mutated oncogenes, such as rising mucin-producing capacity with RAS overexpression, and mutated tumor suppressor genes—including <italic>PTEN </italic>eliciting cell hypertrophy, <italic>RB1 </italic>dictating neuroendocrine differentiation, and <italic>TRP53</italic> encouraging sarcomatous transformation. Familiarity with the concept of genetic addiction, as well as the ability to recognize such regular genomic-phenotypic relationships, are of paramount importance for comparative pathologists who are engaged in phenotyping genetically engineered mice to help unravel genomic intricacies in both health and disease.</p>
</abstract>
<kwd-group>
<kwd>genetic addiction</kwd>
<kwd>genetically engineered mouse model</kwd>
<kwd>oncogene addiction</kwd>
<kwd>pathway pathology</kwd>
<kwd>phenotype</kwd>
<kwd>Pten</kwd>
<kwd>Ras</kwd>
<kwd>Rb</kwd>
<kwd>Trp53</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0300985811430962">
<title>Some Genetic Mutations Can Be “Seen” Under the Microscope</title>
<p>The concept that specific etiologic agents can yield consistent morphological changes is a traditional foundation of pathology. The classic example is infectious disease, where the basic patterns of microbe-induced inflammation are suppurative infiltrates for acute bacterial infections, granulomatous reactions for chronic bacterial and fungal infections, lymphocytic aggregates (often perivascular) for many viruses, and eosinophilic influx for metazoan parasites. In like manner, specific gene abnormalities in certain human cancers can be visualized by the pathologist as stereotypical structural changes in malignant tissues. For instance, in humans, the outcome of mutations to the <italic>BRCA1</italic> gene, which encodes a tumor suppressor protein with DNA repair functions, is visible in the breast as medullary carcinomas and in the ovaries as serous carcinomas. Conversely, the loss of E-cadherin in human breast cancer results in a lobular pattern.<sup>
<xref ref-type="bibr" rid="bibr3-0300985811430962">3</xref>,<xref ref-type="bibr" rid="bibr21-0300985811430962">21</xref>,<xref ref-type="bibr" rid="bibr24-0300985811430962">24</xref>,<xref ref-type="bibr" rid="bibr29-0300985811430962">29</xref>,<xref ref-type="bibr" rid="bibr32-0300985811430962">32</xref>,<xref ref-type="bibr" rid="bibr104-0300985811430962">104</xref>,<xref ref-type="bibr" rid="bibr109-0300985811430962">109</xref>
</sup> The recognition that certain genetic abnormalities are reliably connected to distinct patterns of morphological abnormalities represents an important new paradigm in cancer biology.</p>
<p>This recognition has been formalized during the past decade as the concept of “oncogene addiction.” This hypothesis, which emerged in the literature between 2000 and 2002, states that neoplasms depend on continued expression of one or more oncogenes for maintenance of the malignant phenotype. This premise is supported by findings in some inducible mouse models of human cancer in which tumor regression occurs after a particular oncogene has been “switched off.”<sup>
<xref ref-type="bibr" rid="bibr134-0300985811430962">134</xref>
</sup> For example, persistent expression of c-<italic>Myc</italic> in murine hematopoietic lineages results in T cell and myeloid leukemias, whereas events that inactivate c-<italic>Myc</italic> in leukemia cells lead to a rapid decline in cell division in conjunction with a pronounced rise in apoptosis.<sup>
<xref ref-type="bibr" rid="bibr30-0300985811430962">30</xref>
</sup> The similar concept of “tumor suppressor gene addiction” has been developed as an explanation for the phenomenon that most tumors require lasting inactivation of one or more tumor suppressor genes to ensure continuation of the malignant phenotype. The basis of this concept is that neoplasms will regress or disappear once the function of the missing tumor suppressor gene is restored. The idea is bolstered by studies in mouse cancer models where regression of hepatocellular carcinomas, lymphomas, and sarcomas may be achieved upon restoration of <italic>TRP53</italic> function.<sup>
<xref ref-type="bibr" rid="bibr130-0300985811430962">130</xref>,<xref ref-type="bibr" rid="bibr138-0300985811430962">138</xref>
</sup> A recent review has revisited the concept of “gene addiction” and broadened its meaning to include both oncogene addiction and nononcogene addiction (NOA).<sup>
<xref ref-type="bibr" rid="bibr74-0300985811430962">74</xref>
</sup> NOA-related genes do not necessarily initiate cancer but instead play critical roles in cancer progression and biological behavior because they encode various molecules involved in almost all critical signaling pathways. Because NOA genes are usually downregulated or lost in cancer, they too fit under the broad umbrella of “tumor suppressor genes.”</p>
<p>As the catalog of new mouse models of human cancer grows, the link between certain oncogenes and/or tumor suppressor genes and specific cancer subtypes is increasingly apparent. Together, these data indicate that “genetic addiction”—regardless of whether the genetic abnormality befalls an oncogene, a classic tumor suppressor gene, or a NOA gene—is a critical paradigm for understanding the relationship between genome disruption and neoplastic transformation. An obvious but nonetheless important corollary to this concept is that genetically engineered mouse models (GEMMs) in which neoplasms develop will become an increasingly important tool for linking specific cancer phenotypes to unique genetic signatures.</p>
</sec>
<sec id="section2-0300985811430962">
<title>Phenotypes Linked to a Given Genetic Addiction May Be Similar Across Species</title>
<p>The goal of comparative pathology, and indeed of most biomedical research, is to extrapolate findings from animal studies to better comprehend human disease. Recent data suggest that “genetic addictions” in human neoplasms may be shared by their murine counterparts. The reverse may be equally true, in which case new GEMMs of neoplasia hold substantial promise for unraveling the molecular intricacies of at least some human cancers.</p>
<p>An important multispecies example of a specific genetic addiction leading to a particular constellation of cancer phenotypes may be found in the spectrum of urinary bladder cancers that develop in humans and mice. The main morphological signatures of neoplasia in this organ are papillary outgrowths in benign lesions versus anaplasia and invasiveness in their malignant counterparts. Up to 90% of benign transitional cell tumors of the urinary bladder in humans have an activating mutation of the <italic>HRAS1</italic> oncogene. A transgenic mouse model that expresses an activated <italic>Hras1</italic> in the urinary bladder epithelium develops urinary bladder tumors with morphologic features identical to those seen in humans, thereby strengthening the genotype-to-phenotype link.<sup>
<xref ref-type="bibr" rid="bibr84-0300985811430962">84</xref>
</sup> In contrast, invasive transitional cell carcinomas in humans rarely have an <italic>HRAS</italic> mutation and are addicted, instead, to the sustained loss of both the <italic>RB</italic> and <italic>TRP53</italic> tumor suppressor genes. The genotype-to-phenotype relationship again is confirmed in the mouse using a model in which expression of the simian virus 40 (SV40) T antigen, which blocks both RB and TRP53 specifically in the urothelium, leads to induction of invasive transitional cell tumors instead of benign papillary masses.<sup>
<xref ref-type="bibr" rid="bibr137-0300985811430962">137</xref>,<xref ref-type="bibr" rid="bibr142-0300985811430962">142</xref>
</sup>
</p>
<p>Outside the cancer realm, the intimate connection between <italic>RAS</italic> expression and differentiation of mucin-producing cells is another example of the specific morphologic manifestation of certain genes. In humans, activation of the <italic>RAS</italic> pathway is implicated in mucin overproduction by intestinal and respiratory epithelia.<sup>
<xref ref-type="bibr" rid="bibr62-0300985811430962">62</xref>,<xref ref-type="bibr" rid="bibr67-0300985811430962">67</xref>
</sup> In mice, mucin-secreting cells are also addicted to <italic>RAS</italic>, even in organs that do not normally produce mucin (such as the prostate gland and the pancreas). Mice expressing activated <italic>RAS</italic> specifically in the prostate exhibit extensive goblet cell metaplasia in this organ (<xref ref-type="fig" rid="fig1-0300985811430962">Fig. 1</xref>
).<sup>
<xref ref-type="bibr" rid="bibr114-0300985811430962">114</xref>
</sup> Knowledge of this connection in human tumors prompted researchers to investigate the impact of <italic>Ras</italic> function in the unexpected phenotype of intestinal metaplasia seen in the prostate of <italic>Trp63-</italic>deficient mice. Once again, the role of genetic addiction in promoting a specific phenotypic evolution proved true: intestinal metaplasia in the prostate of these animals was related to activation of the <italic>Ras</italic> pathway.<sup>
<xref ref-type="bibr" rid="bibr59-0300985811430962">59</xref>
</sup> In the pancreas, a <italic>KRAS</italic> mutation is associated with a majority of human pancreatic ductal carcinomas (PDACs)<sup>
<xref ref-type="bibr" rid="bibr2-0300985811430962">2</xref>
</sup> and is sufficient to induce PDAC in the mouse.<sup>
<xref ref-type="bibr" rid="bibr86-0300985811430962">86</xref>
</sup> Interestingly, pancreatic intraductal neoplasia (PanIN), which is the precursor of PDAC, harbors a <italic>KRAS</italic> mutation and also is characterized by extensive mucinous metaplasia of the ductal epithelium. Accordingly, it is not surprising that other malignant neoplasms that arise from mucin-producing tissues, such as colorectal and lung carcinomas in humans, are addicted to <italic>KRAS</italic> mutations as well.<sup>
<xref ref-type="bibr" rid="bibr31-0300985811430962">31</xref>
</sup> Following suit, carcinoma of the salivary gland, with its prominent mucinous cell population, can be induced by targeting mutated <italic>Kras</italic> to the keratin 5 promoter in mice.<sup>
<xref ref-type="bibr" rid="bibr103-0300985811430962">103</xref>
</sup>
</p>
<fig id="fig1-0300985811430962" position="float">
<label>Figure 1.</label>
<caption>
<p>Prostate, 5-month-old probasin-<italic>HRas</italic> (G12V) mouse (C57BL/6 × FVB background). <italic>Ras</italic>-associated mucinous metaplasia is indicated by numerous swollen, pale goblet cells (a, hematoxylin and eosin) containing mucin in their cytoplasm (b, pink globules stained for periodic acid-Schiff).</p>
</caption>
<graphic xlink:href="10.1177_0300985811430962-fig1.tif"/>
</fig>
<p>Connections between gene addictions and certain stereotypic phenotypes are more readily identified in GEMMs since the initiating genetic lesion is known. Mouse mammary tumor models provide many good examples of genetic addiction and “pathway pathology.” For instance, tumors generated by the <italic>Wnt1</italic> transgene and other genes in the <italic>Wnt</italic> pathway, such as <italic>Wnt10b</italic>, <italic>Ctnnb1 </italic>(β-catenin), and <italic>Gsk3β</italic>, have heterogeneous but essentially similar morphologic features, including a combination of acinar and glandular patterns, abundant stroma, areas of squamous metaplasia, and well-organized myoepithelium, a feature that is rarely seen in other mammary tumors (<xref ref-type="fig" rid="fig2-0300985811430962">Fig. 2</xref>
).<sup>
<xref ref-type="bibr" rid="bibr39-0300985811430962">39</xref>,<xref ref-type="bibr" rid="bibr110-0300985811430962">110</xref>
</sup> The so-called Wnt tumors, which exhibit tubular, glandular, and cribriform patterns, are very different from the distinctive solid carcinomas resulting from a <italic>Erbb2</italic>-<italic> (Her-2/neu</italic>) activating mutation of the epidermal growth factor receptor (<italic>EGFR</italic>) gene (<xref ref-type="fig" rid="fig3-0300985811430962">Fig. 3</xref>
).<sup>
<xref ref-type="bibr" rid="bibr4-0300985811430962">4</xref>,<xref ref-type="bibr" rid="bibr85-0300985811430962">85</xref>,<xref ref-type="bibr" rid="bibr110-0300985811430962">110</xref>
</sup> Another example comes from mice lacking E-cadherin and <italic>Trp53</italic>, which develop mammary tumors with lobular morphology just like their human counterparts.<sup>
<xref ref-type="bibr" rid="bibr24-0300985811430962">24</xref>
</sup> Importantly, lobular mammary carcinomas, as well as the solid, comedo-carcinomas displayed by <italic>Erbb2</italic>-mutant mice, closely resemble the human tumor they emulate but are rare as spontaneous lesions in the mouse mammary gland.<sup>
<xref ref-type="bibr" rid="bibr4-0300985811430962">4</xref>,<xref ref-type="bibr" rid="bibr128-0300985811430962">128</xref>
</sup>
</p>
<fig id="fig2-0300985811430962" position="float">
<label>Figure 2.</label>
<caption>
<p>Mammary gland neoplasm, 6-month-old MMTV-<italic>rtTA</italic>-pA/TetO-Wnt-1/p53<sup>–/–</sup> mouse (FVB background). This stereotypical Wnt-1 tumor is an adenocarcinoma that exhibits common Wnt-associated traits such as intermingled tubular, glandular, and cribriform patterns with a prominent, continuous myeopithelial layer highlighted by intense α-smooth muscle actin (α-SMA) expression. Continuous α-SMA-positive basal layers are rarely seen in non-Wnt mammary tumors. This pattern of Wnt-related changes is also seen in spontaneous mammary neoplasms induced by mouse mammary tumor virus (MMTV). Anti-α-SMA indirect immunohistochemistry with hematoxylin counterstain.</p>
</caption>
<graphic xlink:href="10.1177_0300985811430962-fig2.tif"/>
</fig>
<fig id="fig3-0300985811430962" position="float">
<label>Figure 3.</label>
<caption>
<p>Mammary gland neoplasms, 6-month-old Tg(MMTV-LTR:Neu<sup>ndl</sup>) mouse on the FVB background (a) and human (b). Aberrant <italic>Her2/neu</italic> expression is associated with a solid intraductal growth pattern with no evidence of glandular or tubular differentiation. Similar solid carcinomas develop in tetracycline-controlled <italic>Her2/neu</italic> conditional transgenic mice (8-month-old, MMTV-<italic>rtTA</italic>-pA/TetO-Neu<sup>ndl</sup>, FVB construct) treated with doxycycline (0.1 mg/ml for 6 weeks) (c) and regress within 48 hours after doxycycline withdrawal (d), clearly demonstrating the principle of oncogene addiction. This tumor type is not seen in mice that spontaneously develop neoplasms following infection with the mouse mammary tumor virus (MMTV). Hematoxylin and eosin.</p>
</caption>
<graphic xlink:href="10.1177_0300985811430962-fig3.tif"/>
</fig>
<p>Sometimes the genetic addiction happens at a broader level and does not necessarily imply a specific morphologic feature as much as an entire tumor phenotype. Burkitt lymphoma, mouse plasmacytoma, and rat plasmacytomas, all of which are driven by a <italic>c-Myc</italic> habit,<sup>
<xref ref-type="bibr" rid="bibr51-0300985811430962">51</xref>,<xref ref-type="bibr" rid="bibr143-0300985811430962">143</xref>
</sup> and human pancreatic adenocarcinoma, with its strong dependence on <italic>KRAS </italic>mutation,<sup>
<xref ref-type="bibr" rid="bibr139-0300985811430962">139</xref>
</sup> are examples of this broader relationship. Recently, another link between morphologic appearance and genetic constitution has been identified when poorly differentiated (by histopathologic assessment) basal-like breast cancers, glioblastomas, and urinary bladder cancers were found to overexpress 3 genes (<italic>Nanog</italic>, <italic>Pou5f1 </italic>[<italic>Oct-4</italic>], and <italic>Sox2</italic>) that comprise a genetic signature similar to that of embryonic stem cells.<sup>
<xref ref-type="bibr" rid="bibr7-0300985811430962">7</xref>
</sup> Therefore, a reasonable expectation is that the discerning comparative pathologist will ask whether other poorly differentiated tumors carry a similar molecular signature. Such questions provide the basis for rapid advances in understanding new links between specific genes and particular morphologic patterns.</p>
<p>In summary, an increasing number of genetic addictions will be recognized as data on gene function are collected via phenotyping of new GEMMs. By noting the unique morphologic characteristics of certain gene/cell-type interactions, the pathologist quite often can make rational predictions regarding the possible molecular pathways that might be affected in certain tumor types. Knowledge of these genetic addictions or tendencies may also be useful in interpreting unexpected outcomes when using mouse models to explore mechanisms of human disease.</p>
</sec>
<sec id="section3-0300985811430962">
<title>Tumor Suppressor Gene Addictions</title>
<p>Proteins encoded by tumor suppressor genes have a wide range of functions within the cell, but all have one trait in common: they prevent uncontrolled cell proliferation and growth and therefore decrease the likelihood of cancer development. The 2 prototypical genes in this family are <italic>RB</italic>, the first tumor suppressor gene to be discovered,<sup>
<xref ref-type="bibr" rid="bibr54-0300985811430962">54</xref>
</sup> and <italic>TRP53</italic>. The importance of <italic>RB </italic>is illustrated by the occurrence of <italic>RB</italic> deficiency or disruption of <italic>RB</italic>-regulated pathways in many human cancers.<sup>
<xref ref-type="bibr" rid="bibr133-0300985811430962">133</xref>
</sup> In contrast, <italic>TRP53</italic> gained its reputation because it lies at the crossroads of many systems designed to detect and repair DNA damage and thus has the ability to halt cell division and eliminate defective cells before they can threaten the health of the organ or the survival of the individual.</p>
<p>Traditionally, tumor suppressor genes have been classified into 2 types, the “gatekeepers” and the “caretakers.” Gatekeepers are the classic tumor suppressor genes, such as <italic>RB </italic>and<italic> TRP53</italic>. These genes encode proteins that prevent unruly cell proliferation by halting the cell cycle and/or inducing apoptosis. When compared to <italic>RB</italic> and <italic>TRP53</italic>, the more recently identified but extremely important <italic>PTEN </italic>(phosphatase and tensin homolog) gene has many functions related to cell survival and motility and can also be classified as a gatekeeper because it indirectly activates the apoptotic machinery. In contrast, the caretakers are responsible for maintaining genome integrity and usually function as DNA repair genes; examples include <italic>BRCA1</italic> and <italic>BRCA2</italic>. Some genes with tumor suppressor functions, however, do not fall into either of these 2 categories directly and have triggered the recent recognition of a new tumor suppressor gene class: metastasis suppressors. The prototype of this new division is <italic>CD82</italic> (<italic>KAI1</italic>).<sup>
<xref ref-type="bibr" rid="bibr71-0300985811430962">71</xref>,<xref ref-type="bibr" rid="bibr120-0300985811430962">120</xref>
</sup> At a broader level, tumor suppressor genes that may not be sufficient to elicit neoplasia but that play a key role in modifying cancer phenotype can be referred to as NOA genes.<sup>
<xref ref-type="bibr" rid="bibr74-0300985811430962">74</xref>
</sup>
</p>
<p>The separation of tumor suppressor genes into the above categories has facilitated the understanding of many aspects of cancer biology. However, although the loss of certain tumor suppressor genes can be “seen” under the microscope, the implications of the different categories, if any, remain unknown. In the next section, we explore the “addictive effect” of 3 tumor suppressor genes—<italic>RB</italic>, <italic>TRP53</italic> and <italic>PTEN</italic>—as seen from the pathologist’s perspective.</p>
</sec>
<sec id="section4-0300985811430962">
<title>RB Addiction Mediates Neuroendocrine Differentiation and Unique Epithelial Phenotypes</title>
<sec id="section5-0300985811430962">
<title>Molecular Mechanisms</title>
<p>
<italic>RB</italic> encodes a pocket protein, pRB, that acts as the gatekeeper of an important checkpoint of the cell cycle (the “restriction” or R point) at the end of the G1 growth phase. If the cell progresses past this point, then it is committed to finish the cell cycle, independent of external stimuli. In its active form, hypophosphorylated pRB binds transcription factors of the E2F family. Most of the E2F transcription factors are bound to DNA to the promoter regions of target genes, whose products will then move the cell into the S phase (for DNA synthesis). When associated with pRB, the E2Fs fail to activate transcription of these genes, and the cell either remains in G1 or reverts to the G0 resting phase. Conversely, hyperphosphorylation of pRB renders it inactive and results in the release of the E2F factors and subsequent gene transcription. To regulate this process, the cell counts on the presence of cyclins and cyclin-dependent kinases (CDKs), which act to phosphorylate pRB, and on inhibitors of CDKs, which remove phosphate groups from pRB.<sup>
<xref ref-type="bibr" rid="bibr41-0300985811430962">41</xref>,<xref ref-type="bibr" rid="bibr99-0300985811430962">99</xref>,<xref ref-type="bibr" rid="bibr133-0300985811430962">133</xref>
</sup>
</p>
<p>The active form of pRB also represses transcription by remodeling chromatin structure through interaction with proteins involved in nucleosome remodeling, histone acetylation, deacetylation, and methylation.<sup>
<xref ref-type="bibr" rid="bibr75-0300985811430962">75</xref>
</sup> <italic>RB</italic> gene inactivation is most frequently achieved through chromosomal mutations (such as in retinoblastoma tumor development) followed by loss of heterozygosity<sup>
<xref ref-type="bibr" rid="bibr90-0300985811430962">90</xref>
</sup> that result in complete loss of <italic>RB</italic> function. Functional inactivation of pRB can also occur by viral oncoprotein binding; this is the main mechanism of pRB loss in uterine cervical cancer, mesothelioma, and Burkitt lymphoma associated with AIDS.<sup>
<xref ref-type="bibr" rid="bibr23-0300985811430962">23</xref>,<xref ref-type="bibr" rid="bibr35-0300985811430962">35</xref>,<xref ref-type="bibr" rid="bibr57-0300985811430962">57</xref>
</sup> To confound matters further, 2 other pocket proteins from the RB family, named p107 and p130, have similar or overlapping functions to pRB and may play a role in mouse cancer. These 2 RB-related proteins have not been directly implicated in human carcinogenesis.<sup>
<xref ref-type="bibr" rid="bibr135-0300985811430962">135</xref>
</sup>
</p>
<p>Although alterations of 1 or more proteins within the RB pathway are common in most human cancers, loss of<italic> RB</italic> itself is mainly associated with sporadic retinoblastomas and small cell lung carcinomas (a neuroendocrine tumor).<sup>
<xref ref-type="bibr" rid="bibr36-0300985811430962">36</xref>,<xref ref-type="bibr" rid="bibr135-0300985811430962">135</xref>
</sup> Furthermore, germline mutation of <italic>RB</italic> results mostly in retinoblastomas and osteosarcomas. This narrow range of malignancies suggests that <italic>RB</italic> has cell type–specific functions when it comes to tumor suppression. In the mouse, the cell-specific effects of germline <italic>Rb</italic> mutation are even more remarkable, and a distinctive neuroendocrine preference emerges with manifestations in many organs.</p>
</sec>
<sec id="section6-0300985811430962">
<title>Phenotypic Traits of <italic>
<italic>RB</italic>
</italic> Mutations</title>
<p>
<italic>Rb </italic>knockout mice perish as embryos, but <italic>Rb<sup>+/–</sup>
</italic> animals have an increased incidence of several neuroendocrine tumors such as adrenal medullary pheochromocytomas, pituitary carcinomas of the anterior and intermediate lobes, and thyroid medullary carcinomas.<sup>
<xref ref-type="bibr" rid="bibr45-0300985811430962">45</xref>,<xref ref-type="bibr" rid="bibr49-0300985811430962">49</xref>,<xref ref-type="bibr" rid="bibr93-0300985811430962">93</xref>
</sup> <italic>Rb</italic>-deficient chimeras develop the same tumor spectrum described for heterozygous knockout animals.<sup>
<xref ref-type="bibr" rid="bibr136-0300985811430962">136</xref>
</sup> Neither <italic>Rb</italic> heterozygous nor <italic>Rb<sup>–/–</sup>
</italic> chimeric mice develop retinoblastoma. In fact, retinoblastoma fails to develop in mice even when <italic>Rb</italic> disruption is targeted to the retina via the photoreceptor-specific IRBP (interphotoreceptor retinoid binding protein) promoter. Instead, IRBP-<italic>Rb<sup>–/–</sup>
</italic> mice develop pituitary tumors and pineal gland tumors.<sup>
<xref ref-type="bibr" rid="bibr132-0300985811430962">132</xref>
</sup> The absence of retinoblastoma in these 3 lines of <italic>Rb-</italic>deficient mice is likely due to the functional overlap of p107 because the <italic>Rb<sup>–/–</sup>;p107<sup>–/–</sup>
</italic> chimera develops retinoblastoma with inner nuclear layer differentiation.<sup>
<xref ref-type="bibr" rid="bibr107-0300985811430962">107</xref>
</sup> In summary, germline <italic>Rb</italic> deficiency in mice tends to manifest morphologically in the form of neuroendocrine tumors.</p>
<p>Recognizing that, at least in the mouse, neuroendocrine tumors are addicted to <italic>Rb</italic> deficiency provides ample grounds for asking several important questions. For instance, is <italic>Rb</italic> involved in the pathogenesis of neuroendocrine tumors in mouse models that are not necessarily based on engineered <italic>Rb</italic> loss? This possibility has been investigated in <italic>Men1<sup>+/–</sup>
</italic> mice, which develop the same range of neuroendocrine neoplasias displayed by people who present with hereditary type 1 multiple endocrine neoplasia syndrome because they harbor mutations in the <italic>MEN-1</italic> gene. The overlapping phenotype of<italic> Rb<sup>+</sup>
<sup>/–</sup>
</italic> and <italic>Men1<sup>+</sup>
<sup>/–</sup> </italic>mice has allowed scientists to identify interactions between these 2 genes in a cell lineage–specific manner. In particular, evidence that MEN1 regulates RB phosphorylation in certain cell types offers clues toward a more concrete link between RB function and neuroendocrine neoplasia.<sup>
<xref ref-type="bibr" rid="bibr81-0300985811430962">81</xref>
</sup>
</p>
<p>Another important question is whether altered expression of RB family members may lead to the genesis of other tumor types. The premise has been explored using a mouse model of prostate cancer named TgT<sub>121</sub>. This transgenic line carries a truncated version of the SV40 large T antigen that binds pRB, p107, and p130 simultaneously, but it differs from other SV40 constructs because it does not bind TRP53.<sup>
<xref ref-type="bibr" rid="bibr123-0300985811430962">123</xref>
</sup> The T<sub>121</sub> SV40 fragment has been tagged to promoters specific to prostate (ARR2), mammary gland (Wap), and choroid plexus (LPV), at which sites it induces epithelial tumors.<sup>
<xref ref-type="bibr" rid="bibr43-0300985811430962">43</xref>,<xref ref-type="bibr" rid="bibr73-0300985811430962">73</xref>,<xref ref-type="bibr" rid="bibr112-0300985811430962">112</xref>
</sup> These lesions, although located in 3 very different, nonneuroendocrine organs, share several morphologic similarities, including a tendency toward epithelial dysplasia and a high nuclear-to-cytoplasmic ratio. A connection between <italic>Rb</italic> and certain features of epithelial proliferation becomes clearer when prostate-specific T<sub>121</sub> mice are examined.<sup>
<xref ref-type="bibr" rid="bibr44-0300985811430962">44</xref>
</sup> These mutants exhibit extensive prostatic dysplasia characterized by crowded, tufted epithelium and hyperchromatic nuclei. When these mice are crossed to <italic>Trp53<sup>–/–</sup>
</italic> mice, a significant degree of stromal proliferation and occasional stromal tumors are added to the repertoire of epithelial lesions. Although T<sub>121</sub> mice develop hyperplasias, dysplasias, and microinvasive adenocarcinomas, prostatic conditional <italic>Rb</italic> knockout animals have minimal lesions, if any, which may be regulated by intact p107 and/or p130 in the latter.<sup>
<xref ref-type="bibr" rid="bibr44-0300985811430962">44</xref>,<xref ref-type="bibr" rid="bibr76-0300985811430962">76</xref>
</sup> Interestingly, T<sub>121</sub>;<italic>Trp53</italic> double knockout mice have prostatic lesions identical to those found in TRAMP (transgenic adenocarcinoma of the mouse prostate) mice, which harbor the complete SV40 transgene.<sup>
<xref ref-type="bibr" rid="bibr34-0300985811430962">34</xref>,<xref ref-type="bibr" rid="bibr115-0300985811430962">115</xref>
</sup> This finding is not surprising as intact SV40 blocks both pRb and TRP53, which is exactly the genetic background of the double cross mentioned above.</p>
<p>A third important question is to define the nature of the genetic addictions that determine whether animals with <italic>Rb</italic> deficiencies will develop neuroendocrine tumors, epithelial neoplasms, or both. For example, T<sub>121</sub>;<italic>Trp53<sup>–/–</sup>
</italic> mice do not develop neuroendocrine tumors, but such malignancies are common in TRAMP mice.<sup>
<xref ref-type="bibr" rid="bibr19-0300985811430962">19</xref>
</sup> This observation is important because studying the net genetic differences between these 2 models may shed light on the yet unknown molecular pathogenesis of SV40-induced neuroendocrine tumors.<sup>
<xref ref-type="bibr" rid="bibr20-0300985811430962">20</xref>
</sup> Genesis of neuroendocrine neoplasia could be a strain-related phenomenon because T<sub>121</sub>;<italic>Trp53<sup>–/–</sup>
</italic> mice have a mixed genetic background with a strong C57BL/6 component; this strain is known to develop neuroendocrine tumors much later and less frequently than FVB mice.<sup>
<xref ref-type="bibr" rid="bibr115-0300985811430962">115</xref>
</sup> Promoter specificity will also need to be considered because the probasin promoter used to target the prostate in the TRAMP model is also expressed in the prostatic stroma, whereas ARR2 (the promoter used in TgT<sub>121</sub>) is thought to be restricted to the epithelium.<sup>
<xref ref-type="bibr" rid="bibr141-0300985811430962">141</xref>
</sup> Differences in cell lineages suffering the disruption of both tumor suppressor genes also may play a role because <italic>Trp53<sup>–/–</sup> </italic>is a germline mutant (lost globally) in the T<sub>121</sub>;<italic>Trp53<sup>–/–</sup>
</italic> animals but is inactivated simultaneously with <italic>Rb</italic> and restricted to the prostate in the TRAMP model.</p>
<p>It is important to keep in mind that identical mutations (i.e. genetic addictions) may exhibit different phenotypic responses in mice and men. Besides the overlapping role of other pocket proteins, RB functions differently in the mouse when compared to humans. Murine cells have many-fold lower levels of RB protein, and the gene does not bind to the promoter regions of many proapoptotic murine genes that are considered its targets in humans.<sup>
<xref ref-type="bibr" rid="bibr140-0300985811430962">140</xref>
</sup> Furthermore, mice with similar genetic addictions but distinct genetic backgrounds may express divergent structural changes. Comparative pathologists and researchers using GEMMs to explore human disease mechanisms should be aware of such differences to correctly translate mouse data to human disease.</p>
</sec>
</sec>
<sec id="section7-0300985811430962">
<title>
<italic>TRP53</italic> Addiction Mediates a Spindle Habit</title>
<sec id="section8-0300985811430962">
<title>Molecular Mechanisms</title>
<p>In 1979, researchers were using immune sera from mice and hamsters bearing tumors induced by SV40 to study murine cell lines immortalized and transformed by the viral antigens. They found that a protein slightly smaller than 54 kD, subsequently called p53, immunoprecipitated along with SV40 large T and small t antigens.<sup>
<xref ref-type="bibr" rid="bibr42-0300985811430962">42</xref>
</sup> Using the same immune sera, TRP53 was also detected in 2 different, uninfected murine embryonal carcinoma cell lines. Analogous proteins were present in hamster, monkey, and human cells.<sup>
<xref ref-type="bibr" rid="bibr69-0300985811430962">69</xref>
</sup> Subsequently, cDNA cloned from cells with abnormal and wild-type complements of <italic>Trp53</italic> (obtained from tumor cells and normal cells, respectively) were introduced, together with the <italic>Ras</italic> oncogene, into cultured rat embryonic fibroblasts. Although fibroblasts containing a combination of <italic>Ras</italic> and mutant <italic>Trp53</italic> showed large numbers of transformed spindle cell foci, those harboring <italic>Ras</italic> and wild-type <italic>Trp53</italic> exhibited no transformation. These results suggested that the wild-type <italic>Trp53</italic> gene was a tumor suppressor gene and that its mutant version was associated with neoplastic transformation.<sup>
<xref ref-type="bibr" rid="bibr28-0300985811430962">28</xref>
</sup>
</p>
<p>
<italic>TRP53</italic> responds to many types of injurious stimuli, including DNA damage due to irradiation or genotoxic chemicals, hypoxia, cell starvation or malnutrition (lack of proper nutrients), pH changes, and many other intra- and extracellular stressors by inducing cell cycle arrest and/or apoptosis.<sup>
<xref ref-type="bibr" rid="bibr116-0300985811430962">116</xref>
</sup> Because of its nuclear localization and DNA-binding abilities, the TRP53 protein is considered a transcription factor. It is produced at a constant rate in the cell but has a very short half-life of about 20 minutes. In normal cells, TRP53 levels are very low because the protein is ubiquitinated by MDM2, transported out of the nucleus, and degraded in a proteasome.<sup>
<xref ref-type="bibr" rid="bibr83-0300985811430962">83</xref>
</sup> However, the phosphorylated or activated version of TRP53 becomes stable, cannot be ubiquitinated, and remains in the nucleus, where it can then activate transcription of target genes. For example, ionizing radiation causes double-strand DNA breaks that are sensed by specific proteins that signal through the ATM kinase and its downstream kinase ATR; both of these proteins can phosphorylate TRP53 and protect it from degradation.<sup>
<xref ref-type="bibr" rid="bibr47-0300985811430962">47</xref>,<xref ref-type="bibr" rid="bibr92-0300985811430962">92</xref>
</sup> Cell cycle arrest then ensues so that the damaged cell has a chance to repair its chromosomal defect. If the repair is successful, the cell proceeds through the cycle, but if the damage is excessive, the cell is sent down the apoptotic pathway.<sup>
<xref ref-type="bibr" rid="bibr102-0300985811430962">102</xref>
</sup>
</p>
<p>Most <italic>TRP53</italic> functions depend on the activation of target genes. Examples include CKDN1A (P21), a broad-range CDK inhibitor that allows TRP53 to halt the cell cycle in the G1, S, G2, or M phase; GADD45 and XPC, both of which are responsible for nucleotide excision repair to remedy DNA damage; and BAX, BCL2, and PUMA, which regulate apoptosis. Together, these TRP53 targets act by either causing cell cycle arrest or activating the apoptotic cascade. The choice between these 2 fates depends on such factors as cell type, the severity and duration of the stressful stimulus or genetic damage, and the balance between proapoptotic and antiapoptotic factors. Because of its many critical functions and targets, <italic>TRP53</italic> is considered the central guardian of the genome.<sup>
<xref ref-type="bibr" rid="bibr131-0300985811430962">131</xref>
</sup>
</p>
<p>Almost 3 decades after the discovery of the TRP53 protein, mutation of this important tumor suppressor gene has been identified in more than half of all human cancers (as reported in the R15, November 2010 IARC <italic>TRP53</italic> database). The IARC <italic>TRP53</italic> database carries a compilation of relevant statistics about sporadic and germline mutations, as well as tracks polymorphisms of <italic>TRP53</italic>.<sup>
<xref ref-type="bibr" rid="bibr97-0300985811430962">97</xref>
</sup> This database also contains information regarding the function and structure of the TRP53 protein, as well as a list of existing cell lines and mouse models used to study this critical tumor suppressor gene. According to this database, the highest prevalence of somatic <italic>TRP53</italic> mutations in human neoplasms occurs in solid epithelial tumors affecting organs such as the colon and rectum, esophagus, larynx, liver, lung, ovary, pancreas, and skin. However, germline <italic>TRP53 </italic>mutations, as in Li Fraumeni syndrome (a rare autosomal dominant, hereditary condition predisposing afflicted individuals to many forms of cancer), present a significantly different tumor pattern.</p>
</sec>
<sec id="section9-0300985811430962">
<title>Phenotypic Traits of <italic>TRP53</italic> Mutations</title>
<p>Although breast carcinoma remains the tumor type most commonly associated with germline mutations of <italic>TRP53</italic>, a high incidence of soft tissue sarcomas and tumors of the adrenal gland and brain are also reported in human patients with Li Fraumeni syndrome, pointing toward a shift from induction of carcinomas to sarcomas, especially those having a prominent spindle cell phenotype. The sarcoma predilection is emulated in the <italic>Trp53</italic>-deficient mouse.<sup>
<xref ref-type="bibr" rid="bibr50-0300985811430962">50</xref>
</sup>
</p>
<p>The germline mutation patterns of <italic>TRP53</italic> in humans are partially mirrored by <italic>Trp53-</italic>deficient mice. Mice with homozygous null mutations of <italic>Trp53</italic> develop a high incidence of sarcomas, mainly of soft tissues, second in number only to lymphoma.<sup>
<xref ref-type="bibr" rid="bibr50-0300985811430962">50</xref>
</sup> On the other hand, soft tissue sarcomas are the most common malignancy of <italic>Trp53</italic>-heterozygous mice.<sup>
<xref ref-type="bibr" rid="bibr50-0300985811430962">50</xref>
</sup> Lymphomas in these mice are mainly of thymic origin and are composed of immature, incompletely differentiated T lymphocytes (positive for both CD4<sup>+</sup> and CD8<sup>+</sup>). The different tumor spectra in mice with homozygous and heterozygous deficiencies of <italic>Trp53 </italic>may be due to the different latencies of neoplasms associated with complete versus partial loss of this tumor suppressor gene because <italic>Trp53<sup>–/–</sup>
</italic> mice develop tumors much earlier than do <italic>Trp53<sup>+/–</sup> </italic>animals. Tumor latency is much longer in heterozygous mice because they require a second inactivating mutation or LOH that affects the remaining wild-type <italic>Trp53</italic> allele to develop tumors. Furthermore, the pool of susceptible immature thymocytes prone to neoplastic transformation is much decreased in older animals due to thymic involution, which likely explains the much lower prevalence of lymphomas relative to sarcomas in <italic>Trp53<sup>+/–</sup> </italic>mice.<sup>
<xref ref-type="bibr" rid="bibr50-0300985811430962">50</xref>
</sup>
</p>
<p>Many architectural patterns of sarcomas arise in <italic>Trp53<sup>+/–</sup>
</italic> and <italic>Trp53<sup>–/–</sup>
</italic> mice, but most neoplasms have an overall spindle cell morphology. Tumors such as fibrosarcomas, leiomyosarcomas, and rhabdomyosarcomas with their expected fusiform morphology are common in these animals. However, even hemangiosarcomas and osteosarcomas often have a predominantly spindloid appearance in <italic>Trp53</italic> mutant mice; hemangiosarcomas can be predominantly solid masses of spindle cells with a “bloody appearance” imparted by the presence of relatively few small, tortuous, and indistinct vascular channels, whereas osteosarcomas often appear to arise as a fibroblastic mass that contains a few small foci of osteoid and/or bone production. These observations support a close link between the loss of Trp53 function and a predilection for spindle cell differentiation in mice.</p>
<p>A remarkable illustration of <italic>TRP53</italic>’s propensity to mediate a spindle habit in neoplastic cells is its connection to a specific cancer phenotype called epithelial-to-mesenchymal transition (EMT) type tumors. Another designation for these entities often used in diagnostic reports for human tumors is <italic>carcinosarcoma</italic>. Evidence of a role for <italic>Trp53</italic> in the pathogenesis of EMT tumors in the mouse came from several mouse models in which spindle cell masses with unique immunohistochemical features arose in the mammary gland.<sup>
<xref ref-type="bibr" rid="bibr15-0300985811430962">15</xref>
</sup> The neoplastic spindle cells in these unusual tumors often simultaneously coexpress markers specific for both epithelial and mesenchymal differentiation, such as cytokeratins 8/18 in conjunction with smooth muscle actin (SMA) or vimentin (<xref ref-type="fig" rid="fig4-0300985811430962">Fig. 4</xref>
). Evaluation of cytokeratin expression in these tumors confirms the existence of an indistinct glandular epithelioid pattern (as seen in sections stained with hematoxylin and eosin) within an otherwise spindle cell–rich mass. Characteristic EMT tumors were frequently found in crosses of various mouse mammary tumor models, such as mice with <italic>Brca1<sup>–</sup>
</italic>
<sup>/<italic>–</italic>
</sup> or <italic>Hus</italic>
<sup>+/<italic>–</italic>
</sup> mutations, onto the <italic>Trp53</italic>
<sup>+/<italic>–</italic>
</sup> background.<sup>
<xref ref-type="bibr" rid="bibr22-0300985811430962">22</xref>,<xref ref-type="bibr" rid="bibr72-0300985811430962">72</xref>
</sup> However, cancers with the EMT phenotype were also noted in GEMMs without original disruptions in <italic>Trp53</italic> function, such as animals with systemic null mutations of <italic>Gzmm (Met-1)</italic> and <italic>Met-1AS-OPN</italic> or, more recently, mice with targeted deletion of <italic>Brca1</italic> or <italic>Bard51</italic> in the mammary gland epithelium using an inducible mouse mammary tumor virus (MMTV) promoter (unpublished data).<sup>
<xref ref-type="bibr" rid="bibr52-0300985811430962">52</xref>
</sup> These observations are relevant because EMT tumors are rare in wild-type mice, which further emphasizes the causal relationship between <italic>Trp53 </italic>mutations and spindle cell differentiation in mouse tumors.</p>
<fig id="fig4-0300985811430962" position="float">
<label>Figure 4.</label>
<caption>
<p>Mammary gland neoplasm, 9-month-old <italic>p53<sup>+/–</sup>;Hus1</italic>
<sup>+/<italic>–</italic>
</sup> mouse (mixed C57BL/6, S129 background). A common phenotype of the aberrant <italic>Trp53</italic> genotype is spindle cell differentiation, or the epithelial-to-mesenchymal transition (EMT) phenotype. The distribution of 2 epithelial markers—keratin-14 (a) and keratin-8 (b)—overlaps with the location of 2 mesenchymal differentiation markers—α-smooth muscle actin (c) and vimentin (d). Importantly, the neoplastic epithelioid and spindle cell populations both abundantly express 2 or more of the intermediate filaments and α-smooth muscle actin. Indirect immunoperoxidase procedures with hematoxylin counterstain, performed on serial sections.</p>
</caption>
<graphic xlink:href="10.1177_0300985811430962-fig4.tif"/>
</fig>
<p>As with the link between <italic>Rb</italic> disruption and the neuroendocrine phenotype, the recognition of <italic>TRP53</italic>’s spindle habit brings forth additional lines of inquiry. One obvious need is to explain how the link between cell shape and <italic>TRP53</italic> abnormalities is regulated from the molecular perspective. In the case of the EMT phenomenon, it is reasonable to suggest a possible connection between <italic>Trp53</italic> and genes known to be involved in epithelial-to-mesenchymal transitions, such as the transcription factors <italic>Snai2 (Slug)</italic>, <italic>Snai1 (Snail)</italic>, and <italic>Twist1</italic>. In support of this reasoning is the fact that TWIST1 has been recently shown to interact directly with TRP53, disturbing its tumor suppressor gene functions.<sup>
<xref ref-type="bibr" rid="bibr117-0300985811430962">117</xref>
</sup> It will also be important to investigate the status of adhesion molecules such as E-cadherin in EMT tumors because <italic>Snail</italic> blocks E-cadherin expression.<sup>
<xref ref-type="bibr" rid="bibr12-0300985811430962">12</xref>
</sup> Doubtless, a combination of molecular changes that participate in mediating the effects of <italic>Trp53</italic> deficiency will be defined during the course of future investigations in this field.</p>
<p>Other epithelial tumors in humans with tendencies toward spindle differentiation, such as adenomyoepitheliomas or mammary gland carcinosarcomas, also harbor <italic>TRP53</italic> mutations.<sup>
<xref ref-type="bibr" rid="bibr5-0300985811430962">5</xref>,<xref ref-type="bibr" rid="bibr40-0300985811430962">40</xref>,<xref ref-type="bibr" rid="bibr101-0300985811430962">101</xref>
</sup> Aggressive myoepithelial carcinomas of the salivary gland with their poorly differentiated spindle cell morphology as well as colonic, cutaneous, esophageal, gastric, ovarian, and uterine carcinosarcomas are also addicted to <italic>TRP53</italic> disruption.<xref ref-type="fn" rid="fn1-0300985811430962">*</xref> Furthermore, <italic>TRP53</italic> mutations are found in sarcomatoid transformation of carcinomas of the kidney and prostate, in sarcomatoid differentiation of squamous cell carcinomas of the skin, and in sarcomatoid tumors of the upper respiratory tract and liver.<sup>
<xref ref-type="bibr" rid="bibr6-0300985811430962">6</xref>,<xref ref-type="bibr" rid="bibr17-0300985811430962">17</xref>,<xref ref-type="bibr" rid="bibr26-0300985811430962">26</xref>,<xref ref-type="bibr" rid="bibr46-0300985811430962">46</xref>,<xref ref-type="bibr" rid="bibr87-0300985811430962">87</xref>,<xref ref-type="bibr" rid="bibr94-0300985811430962">94</xref>
</sup>
</p>
<p>In summary, comparative pathologists faced with a predominantly spindle cell conformation in neoplasms should be prompted to investigate the integrity of the <italic>TRP53</italic> gene. Entities subject to such directed assessment will include sarcomas, carcinomas with spindle cell morphology, and EMT tumors of many organs in both mouse and man. Nuclear features of spindle cell tumors may also provide a clue that TRP53 function has been affected. This latter observation comes from the fact that loss of TRP53 function results in the perpetuation of genomic damage and aneuploidy, which often manifests morphologically as increased nuclear atypia.<sup>
<xref ref-type="bibr" rid="bibr43-0300985811430962">43</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section10-0300985811430962">
<title>
<italic>PTEN</italic> Addiction Promotes an Inflated Cell Image</title>
<sec id="section11-0300985811430962">
<title>Molecular Mechanisms</title>
<p>A relatively new player, the gatekeeper gene <italic>PTEN</italic>, has quickly risen to the forefront of cancer research as a critical tumor suppressor gene because of the increasing evidence for its active participation in numerous human cancers. A high frequency of LOH on chromosome 10q (later narrowed to the bands at 10q21-25) has been demonstrated in many human cancers, including endometrial carcinoma, glioblastoma, malignant melanoma, meningioma, prostate adenocarcinoma, renal cell carcinoma, thyroid follicular carcinoma, and transitional cell carcinoma of the urinary bladder.<sup>
<xref ref-type="fn" rid="fn2-0300985811430962">†</xref>
</sup> Almost simultaneously, the gene responsible for Cowden disease, an autosomal dominant inherited syndrome that results in multiple hamartomas and a variety of cancers, was localized to the same chromosomal arm.<sup>
<xref ref-type="bibr" rid="bibr68-0300985811430962">68</xref>,<xref ref-type="bibr" rid="bibr80-0300985811430962">80</xref>,<xref ref-type="bibr" rid="bibr91-0300985811430962">91</xref>
</sup> Further studies of tumors from patients with Cowden disease led to the discovery of a new tumor suppressor gene at 10q23 by 2 independent groups; the proposed names were <italic>PTEN </italic>(phosphatase and tensin homolog) and<italic> MMAC1 </italic>(mutated in multiple advanced cancers 1).<sup>
<xref ref-type="bibr" rid="bibr64-0300985811430962">64</xref>,<xref ref-type="bibr" rid="bibr66-0300985811430962">66</xref>,<xref ref-type="bibr" rid="bibr119-0300985811430962">119</xref>
</sup> Shortly after its discovery, <italic>PTEN</italic> mutations also were linked to Bannayan-Riley-Ruvalcaba syndrome and Lhermitte-Duclos disease, 2 other hamartoma disorders in humans related to Cowden disease; <italic>PTEN</italic> was also confirmed to be mutated or deleted in many human tumors.<sup>
<xref ref-type="fn" rid="fn3-0300985811430962">‡</xref>
</sup> Recent investigations in this field have implicated <italic>PTEN</italic> in the genesis of several other human neoplasms—adrenal medullary pheochromocytomas and ovarian and mammary tumors—as well as 2 other autosomal genetic disorders, Proteus syndrome (the “elephant man” disease) and Proteus-like syndromes.<sup>
<xref ref-type="bibr" rid="bibr55-0300985811430962">55</xref>,<xref ref-type="bibr" rid="bibr111-0300985811430962">111</xref>,<xref ref-type="bibr" rid="bibr129-0300985811430962">129</xref>
</sup>
</p>
<p>PTEN is a membrane-bound lipid phosphatase that inhibits the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Upon activation, PI3K converts the precursor phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) to phosphatidylinositol 3,4,5-triphosphate (PIP<sub>3</sub>), an active second messenger that promotes cell survival, growth, and proliferation by activating downstream kinases such as AKT and JNK. PTEN functions to remove a phosphate group from PIP<sub>3</sub>, thereby converting it back to its inactive PIP<sub>2</sub> form and blocking PI3K downstream signaling that leads to enhanced cell growth and division.<sup>
<xref ref-type="bibr" rid="bibr77-0300985811430962">77</xref>
</sup> The AKT kinase isoforms boost cell metabolism and promote both cell survival and angiogenesis by phosphorylating numerous important proteins, including MDM2 (a TPR53 antagonist) as well as BAD and CASP9 (both involved in apoptosis), among many others.<sup>
<xref ref-type="bibr" rid="bibr78-0300985811430962">78</xref>
</sup> JNK, also known as mitogen-activated protein kinase 8 (MAPK8), is important in transcription regulation, cell proliferation, and differentiation.<sup>
<xref ref-type="bibr" rid="bibr10-0300985811430962">10</xref>
</sup> PTEN also plays a role in regulating cell polarity and migration, perhaps via interaction with focal adhesion kinase (FAK).<sup>
<xref ref-type="bibr" rid="bibr33-0300985811430962">33</xref>
</sup> More recently, a role of PTEN in the maintenance of stem cell health in some tissues has also been reported.<sup>
<xref ref-type="bibr" rid="bibr113-0300985811430962">113</xref>
</sup>
</p>
</sec>
<sec id="section12-0300985811430962">
<title>Phenotypic Traits of <italic>PTEN</italic> Mutations</title>
<p>Although <italic>PTEN</italic> does not seem to have a preference for a certain tumor type, its deficiency as a causative and/or contributing event in many hamartoma syndromes unveils a gene addiction that manifests morphologically in tissue overgrowth resulting from more and bigger cells. For instance, Lhermitte-Duclos disease, often associated with Cowden disease, consists of partial macrocephaly with nonneoplastic enlargement of the cerebellum and part of the cerebrum, as well as marked hypertrophy of neurons and glial elements in the affected regions of the brain (Suppl. Fig. S1).<sup>
<xref ref-type="bibr" rid="bibr108-0300985811430962">108</xref>
</sup> In addition, cells lacking PTEN exhibit significantly more metabolic activity and therefore become bigger. The enlargement is mostly due to an abundant cytoplasm with a slightly foamy appearance, likely due to glycogen accumulation resulting from activation of glycogen synthase kinase 3 (GSK3), which is regulated by PI3K.<sup>
<xref ref-type="bibr" rid="bibr13-0300985811430962">13</xref>
</sup> In contrast to lesions caused by <italic>TRP53</italic> loss, where the diminishment of gene repair mechanisms leads to considerable nuclear atypia, the nuclear features in these “inflated” <italic>PTEN</italic>-deficient cells are usually unaltered. This bland nuclear appearance is consistent with the proposed mechanism of <italic>PTEN</italic>, where disruption leads to a cellular “metabolic” dysfunction localized to the cytoplasm rather than accumulation of genetic damage within the nucleus.</p>
<p>Altered <italic>PTEN</italic> expression results in a spectrum of hamartomatous changes that may have profound effects in the developing organism. Mice lacking <italic>Pten</italic> die in utero, whereas <italic>Pten<sup>+/–</sup>
</italic> animals develop numerous hyperplastic and neoplastic lesions involving a number of tissues, including adrenal and thyroid glands, endometrium, the gastrointestinal tract, liver and gallbladder, lymphoid tissues (mainly lymph nodes and thymus), prostate, and the gonads (germ cells and gonadostromal tumors).<sup>
<xref ref-type="bibr" rid="bibr25-0300985811430962">25</xref>,<xref ref-type="bibr" rid="bibr100-0300985811430962">100</xref>,<xref ref-type="bibr" rid="bibr118-0300985811430962">118</xref>,<xref ref-type="bibr" rid="bibr122-0300985811430962">122</xref>
</sup> In the mouse mammary gland, lack of <italic>Pten</italic> (<italic>Pten<sup>–/–</sup>
</italic> conditional knockouts) leads to the development of adenomyoepithelioma, another benign lesion.<sup>
<xref ref-type="bibr" rid="bibr65-0300985811430962">65</xref>
</sup> Although these lesions can reach large sizes, they mostly retain a benign or preneoplastic appearance and behavior unless further genetic changes ensue, such as the loss of the remaining <italic>Pten</italic> allele or combined loss of a <italic>Pten</italic> allele and another tumor suppressor gene, as demonstrated by compound prostate cancer models such as the double conditional <italic>Pten<sup>–/–</sup>;Trp53<sup>–</sup>
<sup>/–</sup>
</italic> mice and <italic>Pten<sup>+/–</sup>;Nkx3-1<sup>+/–</sup>
</italic> mice.<sup>
<xref ref-type="bibr" rid="bibr1-0300985811430962">1</xref>,<xref ref-type="bibr" rid="bibr18-0300985811430962">18</xref>
</sup> This observation is in line with <italic>Pten</italic>’s role as a regulator of hyperplasia and hypertrophy. Furthermore, the diverse lesions in <italic>Pten<sup>+/–</sup>
</italic> mice display characteristic large cells with slightly foamy cytoplasm (Suppl. Fig. S2). In fact, even normal (nonneoplastic) metabolically active cells in <italic>Pten<sup>+/–</sup> </italic>mice, such as hepatocytes and renal tubular epithelial cells, often have abundant foamy cytoplasm. Organomegaly does not come as a surprise in <italic>Pten<sup>+/–</sup>
</italic> mice due to the widespread presence of cytomegaly.<sup>
<xref ref-type="bibr" rid="bibr90-0300985811430962">90</xref>,<xref ref-type="bibr" rid="bibr121-0300985811430962">121</xref>
</sup>
</p>
<p>Further evidence of PTEN’s inflated idea of the cell comes from its role in mediating cardiac muscle hypertrophy, vascular smooth muscle hypertrophy, mesangial hypertrophy in diabetic nephropathies, and hypertrophy of neurons and astrocytes.<sup>
<xref ref-type="bibr" rid="bibr105-0300985811430962">105</xref>
</sup> Here again, consideration of PTEN’s mode of action may help the pathologist understand resulting morphologic manifestations and recognize the possible involvement of this gene or components of its pathway, such as AKT, in the development of certain diseases and cancers.</p>
</sec>
</sec>
<sec id="section13-0300985811430962">
<title>Final Remarks</title>
<p>The evolution of modern pathology has followed the many technological advances that have developed since the use of the first simple microscopes in the 17th century. The subsequent discovery of the cell as the functional unit of living organisms, as well as detailed descriptions of tissue morphology during health and disease, characterized the Renaissance of the biological and medical sciences throughout the 19th century. Today, the marvels of molecular technology appear, at times, to clash with traditional histologic examination as the primary tools for investigating disease. Glass slides are being slowly replaced by digital images as the main platform for diagnosing morphologic changes in diseased tissue, and the traditional blue and pink of the classic hematoxylin and eosin–stained section are slowly being supplanted by multicolor “in silico” genomic and proteomic arrays. The gene, and no longer the cell, is considered the functional unit of all living organisms.</p>
<p>That said, the recognition of often subtle differences in color, shape, and size made the discipline of pathology a cross between straightforward science and changeable art. Technology, from the first histochemical stains to the multitude of <italic>in situ</italic> molecular biology tools currently in use, has helped to transform pathology into a more exact science. Without molecular pathology, morphology is limited, but the reverse is also true. Homogenizing tumors to retrieve DNA, RNA, or protein without knowledge of its morphologic features thrusts us back into the Galenic age of mere lumps and bumps, albeit with a genomic spin. Exact quantification of a genomic signature without considering how the genes relate to structural characteristics is of limited value. It remains important to continually recall that morphology is a result of gene function and that morphology and genetics complement each other on the road to a broader and deeper understanding of cancer and many other diseases.</p>
<p>The goal of this review was to bring to light burgeoning new knowledge regarding the connections between gene expression and particular morphologic phenotypes in cancer biology. By bringing some of these correlations to the forefront, we hope to have heightened the awareness and teased the curiosity of the comparative pathologists engaged in genetically engineered mouse phenotyping and translational medicine. Here we focused on the 3 most important tumor suppressor genes that have been identified to date to exemplify the power of understanding gene-specific structural changes. In both mice and humans, these gatekeeper genes induce fairly stereotypical features: <italic>RB</italic> is related to neuroendocrine differentiation, <italic>TRP53</italic> is highly expressed in spindle cell neoplasms, and <italic>PTEN</italic> is associated with neoplastic and nonneoplastic expansion and enlargement of many cell types. Despite these trends, it is important to remember that there will be many neuroendocrine tumors with a fully functional RB, carcinomas with spindloid features that have intact TRP53 function, and hypertrophic organs and tumors with large foamy cells that have perfectly normal PTEN function. The key is to make the best use of each traditional morphologic and modern molecular tool to better comprehend how genetic changes affect structural traits and how anatomic features can be used to predict the genetic defects that may contribute to disease. It is the comparative pathologist’s responsibility to learn the shades and hues that link aberrant gene function to specific morphologic patterns to contribute effectively to phenotyping the many new genetically engineered mouse strains created every day and to more rapidly affect efforts to reduce and prevent human cancers.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We thank Dr. Gerald Cunha (UCSF) for providing the laboratory space in which some of the genetic addictions described in this manuscript were explored. We thank the Armed Forces Institute of Pathology (AFIP) for making the whole-mount histologic section of the Lhermitte-Duclos disease brain (Suppl. Fig. S1) available for public use. The CD-ROM Version of the Atlas of Tumor Pathology) contains US government work that may be used without restriction. A link to the image within the Pathology Educational Instructional Resource (PEIR) digital library can be found here: <ext-link ext-link-type="uri" xlink:href="http://peir2.path.uab.edu/pdl/dbr.cgi?db=images&amp;uid=default&amp;Collection=*&amp;Collection2=*&amp;Type=*&amp;Type2=*&amp;Description=&amp;syn=num&amp;mh=20&amp;hits=20&amp;File=00405804&amp;view_records=View+Records&amp;view_records=Search">http://peir2.path.uab.edu/pdl/dbr.cgi?db=images&amp;uid=default&amp;Collection=*&amp;Collection2=*&amp;Type=*&amp;Type2=*&amp;Description=&amp;syn=num&amp;mh=20&amp;hits=20&amp;File=00405804&amp;view_records=View+Records&amp;view_records=Search</ext-link>.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0300985811430962">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0300985811430962">
<p>The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: A portion of this work (RDC) was supported by the U01 CA141541, U01 CA141582, and U01 CA105490 grants from the National Cancer Institute’s Mouse Models of Human Cancers Consortium.</p>
</fn>
</fn-group>
<notes>
<fn-group>
<fn fn-type="other" id="fn3-0300985811430962">
<p>*References 9, 11, 53, 60, 63, 79, 82, 88, 89, 95, 124, 125.</p>
</fn>
<fn fn-type="other" id="fn4-0300985811430962">
<p>
<sup>†</sup>References 8, 14, 16, 27, 37, 48, 56, 58, 61, 98, 127.</p>
</fn>
<fn fn-type="other" id="fn5-0300985811430962">
<p>
<sup>‡</sup>References 25, 38, 70, 96, 106, 119, 126.</p>
</fn>
</fn-group>
</notes>
<ref-list>
<title>References</title>
<ref id="bibr1-0300985811430962">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abate-Shen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Banach-Petrosky</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases</article-title>. <source>Cancer Res</source>. <year>2003</year>;<volume>63</volume>(<issue>14</issue>):<fpage>3886</fpage>–<lpage>3890</lpage>.</citation>
</ref>
<ref id="bibr2-0300985811430962">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almoguera</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Forrester</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes</article-title>. <source>Cell</source>. <year>1988</year>;<volume>53</volume>(<issue>4</issue>):<fpage>549</fpage>–<lpage>554</lpage>.</citation>
</ref>
<ref id="bibr3-0300985811430962">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvarez</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>D</given-names>
</name>
</person-group>, <article-title>Chodosh LA. mILC-ing the mouse mammary gland: a model for invasive lobular carcinoma</article-title>. <source>Cancer Cell</source>. <year>2006</year>;<volume>10</volume>(<issue>5</issue>):<fpage>347</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr4-0300985811430962">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrechek</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>PM</given-names>
</name>
<etal/>
</person-group>. <article-title>Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2000</year>;<volume>97</volume>(<issue>7</issue>):<fpage>3444</fpage>–<lpage>3449</lpage>.</citation>
</ref>
<ref id="bibr5-0300985811430962">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reis Filho</surname>
<given-names>JS</given-names>
</name>
<etal/>
</person-group>. <article-title>Expression of ATM, p53, and the MRE11-Rad50-NBS1 complex in myoepithelial cells from benign and malignant proliferations of the breast</article-title>. <source>J Clin Pathol</source>. <year>2004</year>;<volume>57</volume>(<issue>11</issue>):<fpage>1179</fpage>–<lpage>1184</lpage>.</citation>
</ref>
<ref id="bibr6-0300985811430962">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ansari-Lari</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hoque</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Califano</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunohistochemical p53 expression patterns in sarcomatoid carcinomas of the upper respiratory tract</article-title>. <source>Am J Surg Pathol</source>. <year>2002</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1024</fpage>–<lpage>1031</lpage>.</citation>
</ref>
<ref id="bibr7-0300985811430962">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben-Porath</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>VJ</given-names>
</name>
<etal/>
</person-group>. <article-title>An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors</article-title>. <source>Nat Genet</source>. <year>2008</year>;<volume>40</volume>(<issue>5</issue>):<fpage>499</fpage>–<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr8-0300985811430962">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergerheim</surname>
<given-names>US</given-names>
</name>
<name>
<surname>Kunimi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>VP</given-names>
</name>
<etal/>
</person-group>. <article-title>Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma</article-title>. <source>Genes Chromosomes Cancer</source>. <year>1991</year>;<volume>3</volume>(<issue>3</issue>):<fpage>215</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr9-0300985811430962">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bigby</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Charlton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>MV</given-names>
</name>
<etal/>
</person-group>. <article-title>Biphasic sarcomatoid basal cell carcinoma (carcinosarcoma): four cases with immunohistochemistry and review of the literature</article-title>. <source>J Cutan Pathol</source>. <year>2005</year>;<volume>32</volume>(<issue>2</issue>):<fpage>141</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr10-0300985811430962">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blanco-Aparicio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Renner</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Leal</surname>
<given-names>JF</given-names>
</name>
<etal/>
</person-group>. <article-title>PTEN, more than the AKT pathway</article-title>. <source>Carcinogenesis</source>. <year>2007</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1379</fpage>–<lpage>1386</lpage>.</citation>
</ref>
<ref id="bibr11-0300985811430962">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabibi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Martorana</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cappello</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Carcinosarcoma of monoclonal origin arising in a dermoid cyst of ovary: a case report</article-title>. <source>BMC Cancer</source>. <year>2006</year>;<volume>6</volume>:<fpage>47</fpage>.</citation>
</ref>
<ref id="bibr12-0300985811430962">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Perez-Moreno</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rodrigo</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression</article-title>. <source>Nat Cell Biol</source>. <year>2000</year>;<volume>2</volume>(<issue>2</issue>):<fpage>76</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr13-0300985811430962">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantley</surname>
<given-names>LC</given-names>
</name>
</person-group>. <article-title>The phosphoinositide 3-kinase pathway</article-title>. <source>Science</source>. <year>2002</year>;<volume>296</volume>(<issue>5573</issue>):<fpage>1655</fpage>–<lpage>1657</lpage>.</citation>
</ref>
<ref id="bibr14-0300985811430962">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cappellen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gil Diez de Medina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chopin</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder</article-title>. <source>Oncogene</source>. <year>1997</year>;<volume>14</volume>(<issue>25</issue>):<fpage>3059</fpage>–<lpage>3066</lpage>.</citation>
</ref>
<ref id="bibr15-0300985811430962">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardiff</surname>
<given-names>RD</given-names>
</name>
</person-group>. <article-title>Epithelial to mesenchymal transition tumors: fallacious or snail’s pace?</article-title> <source>Clin Cancer Res</source>. <year>2005</year>;<volume>11</volume>(<issue>24, pt 1</issue>):<fpage>8534</fpage>–<lpage>8537</lpage>.</citation>
</ref>
<ref id="bibr16-0300985811430962">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carter</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Ewing</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>WS</given-names>
</name>
<etal/>
</person-group>. <article-title>Allelic loss of chromosomes 16q and 10q in human prostate cancer</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1990</year>;<volume>87</volume>(<issue>22</issue>):<fpage>8751</fpage>–<lpage>8755</lpage>.</citation>
</ref>
<ref id="bibr17-0300985811430962">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>TH</given-names>
</name>
<etal/>
</person-group>. <article-title>Sarcomas and sarcomatoid tumor after radiotherapy of oral squamous cell carcinoma: analysis of 4 cases</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>. <year>2008</year>;<volume>105</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr18-0300985811430962">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Trotman</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Shaffer</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis</article-title>. <source>Nature</source>. <year>2005</year>;<volume>436</volume>(<issue>7051</issue>):<fpage>725</fpage>–<lpage>730</lpage>.</citation>
</ref>
<ref id="bibr19-0300985811430962">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiaverotti</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Couto</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Donjacour</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer</article-title>. <source>Am J Pathol</source>. <year>2008</year>;<volume>172</volume>(<issue>1</issue>):<fpage>236</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr20-0300985811430962">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Couto</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Cardiff</surname>
<given-names>RD</given-names>
</name>
</person-group>. <article-title>The genomic revolution and endocrine pathology</article-title>. <source>Endocr Pathol</source>. <year>2008</year>;<volume>19</volume>(<issue>3</issue>):<fpage>139</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr21-0300985811430962">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crum</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Drapkin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kindelberger</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer</article-title>. <source>Clin Med Res</source>. <year>2007</year>;<volume>5</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr22-0300985811430962">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damonte</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gregg</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Borowsky</surname>
<given-names>AD</given-names>
</name>
<etal/>
</person-group>. <article-title>EMT tumorigenesis in the mouse mammary gland</article-title>. <source>Lab Invest</source>. <year>2007</year>;<volume>87</volume>(<issue>12</issue>):<fpage>1218</fpage>–<lpage>1226</lpage>.</citation>
</ref>
<ref id="bibr23-0300985811430962">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dannenberg</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>te Riele</surname>
<given-names>HP</given-names>
</name>
</person-group>. <article-title>The retinoblastoma gene family in cell cycle regulation and suppression of tumorigenesis</article-title>. <source>Results Probl Cell Differ</source>. <year>2006</year>;<volume>42</volume>:<fpage>183</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr24-0300985811430962">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derksen</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Saridin</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis</article-title>. <source>Cancer Cell</source>. <year>2006</year>;<volume>10</volume>(<issue>5</issue>):<fpage>437</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr25-0300985811430962">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Cristofano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pesce</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cordon-Cardo</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Pten is essential for embryonic development and tumour suppression</article-title>. <source>Nat Genet</source>. <year>1998</year>;<volume>19</volume>(<issue>4</issue>):<fpage>348</fpage>–<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr26-0300985811430962">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dijkhuizen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Van Den Berg</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Van Den Berg</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Genetics as a diagnostic tool in sarcomatoid renal-cell cancer</article-title>. <source>Int J Cancer</source>. <year>1997</year>;<volume>72</volume>(<issue>2</issue>):<fpage>265</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr27-0300985811430962">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Sipe</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Hyytinen</surname>
<given-names>ER</given-names>
</name>
<etal/>
</person-group>. <article-title>PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate</article-title>. <source>Oncogene</source>. <year>1998</year>;<volume>17</volume>(<issue>15</issue>):<fpage>1979</fpage>–<lpage>1982</lpage>.</citation>
</ref>
<ref id="bibr28-0300985811430962">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eliyahu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Raz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gruss</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Participation of p53 cellular tumour antigen in transformation of normal embryonic cells</article-title>. <source>Nature</source>. <year>1984</year>;<volume>312</volume>(<issue>5995</issue>):<fpage>646</fpage>–<lpage>649</lpage>.</citation>
</ref>
<ref id="bibr29-0300985811430962">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esposito</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Chivukula</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dabbs</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study</article-title>. <source>Mod Pathol</source>. <year>2007</year>;<volume>20</volume>(<issue>1</issue>):<fpage>130</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr30-0300985811430962">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Felsher</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Bishop</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Reversible tumorigenesis by MYC in hematopoietic lineages</article-title>. <source>Mol Cell</source>. <year>1999</year>;<volume>4</volume>(<issue>2</issue>):<fpage>199</fpage>–<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr31-0300985811430962">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finberg</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Sequist</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>VA</given-names>
</name>
<etal/>
</person-group>. <article-title>Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features</article-title>. <source>J Mol Diagn</source>. <year>2007</year>;<volume>9</volume>(<issue>3</issue>):<fpage>320</fpage>–<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr32-0300985811430962">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folkins</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Jarboe</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Saleemuddin</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations</article-title>. <source>Gynecol Oncol</source>. <year>2008</year>;<volume>109</volume>(<issue>2</issue>):<fpage>168</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr33-0300985811430962">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franca-Koh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kamimura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Devreotes</surname>
<given-names>PN</given-names>
</name>
</person-group>. <article-title>Leading-edge research: PtdIns(3,4,5)P3 and directed migration</article-title>. <source>Nat Cell Biol</source>. <year>2007</year>;<volume>9</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr34-0300985811430962">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gingrich</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Barrios</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Morton</surname>
<given-names>RA</given-names>
</name>
<etal/>
</person-group>. <article-title>Metastatic prostate cancer in a transgenic mouse</article-title>. <source>Cancer Res</source>. <year>1996</year>;<volume>56</volume>(<issue>18</issue>):<fpage>4096</fpage>–<lpage>4102</lpage>.</citation>
</ref>
<ref id="bibr35-0300985811430962">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodrich</surname>
<given-names>DW</given-names>
</name>
</person-group>. <article-title>The retinoblastoma tumor-suppressor gene, the exception that proves the rule</article-title>. <source>Oncogene</source>. <year>2006</year>;<volume>25</volume>(<issue>38</issue>):<fpage>5233</fpage>–<lpage>5243</lpage>.</citation>
</ref>
<ref id="bibr36-0300985811430962">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gouyer</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gazzeri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bolon</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors</article-title>. <source>Am J Respir Cell Mol Biol</source>. <year>1998</year>;<volume>18</volume>(<issue>2</issue>):<fpage>188</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr37-0300985811430962">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Loss of the chromosomal region 10q23-25 in prostate cancer</article-title>. <source>Cancer Res</source>. <year>1995</year>;<volume>55</volume>(<issue>21</issue>):<fpage>4800</fpage>–<lpage>4803</lpage>.</citation>
</ref>
<ref id="bibr38-0300985811430962">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guldberg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>thor Straten</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Birck</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma</article-title>. <source>Cancer Res</source>. <year>1997</year>;<volume>57</volume>(<issue>17</issue>):<fpage>3660</fpage>–<lpage>3663</lpage>.</citation>
</ref>
<ref id="bibr39-0300985811430962">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gunther</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Moody</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Belka</surname>
<given-names>GK</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis</article-title>. <source>Genes Dev</source>. <year>2003</year>;<volume>17</volume>(<issue>4</issue>):<fpage>488</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr40-0300985811430962">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Myoepithelial carcinoma arising in an adenomyoepithelioma of the breast: case report with immunohistochemical and mutational analysis</article-title>. <source>Pathol Int</source>. <year>2006</year>;<volume>56</volume>(<issue>4</issue>):<fpage>211</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr41-0300985811430962">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harbour</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>DC</given-names>
</name>
</person-group>. <article-title>Rb function in cell-cycle regulation and apoptosis</article-title>. <source>Nat Cell Biol</source>. <year>2000</year>;<volume>2</volume>(<issue>4</issue>):<fpage>E65</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr42-0300985811430962">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>CC.</given-names>
</name>
</person-group> <article-title>p53 tumor suppressor gene: from the basic research laboratory to the clinic—an abridged historical perspective</article-title>. <source>Carcinogenesis</source>. <year>1996</year>;<volume>17</volume>(<issue>6</issue>):<fpage>1187</fpage>–<lpage>1198</lpage>.</citation>
</ref>
<ref id="bibr43-0300985811430962">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cardiff</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group>. <article-title>Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model</article-title>. <source>Cancer Res</source>. <year>2005</year>;<volume>65</volume>(<issue>22</issue>):<fpage>10243</fpage>–<lpage>10254</lpage>.</citation>
</ref>
<ref id="bibr44-0300985811430962">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cardiff</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group>. <article-title>Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis</article-title>. <source>Cell</source>. <year>2005</year>;<volume>123</volume>(<issue>6</issue>):<fpage>1001</fpage>–<lpage>1011</lpage>.</citation>
</ref>
<ref id="bibr45-0300985811430962">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gutsmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Herbert</surname>
<given-names>DC</given-names>
</name>
<etal/>
</person-group>. <article-title>Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance</article-title>. <source>Oncogene</source>. <year>1994</year>;<volume>9</volume>(<issue>4</issue>):<fpage>1021</fpage>–<lpage>1027</lpage>.</citation>
</ref>
<ref id="bibr46-0300985811430962">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Idrees</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gribetz</surname>
<given-names>ME</given-names>
</name>
<etal/>
</person-group>. <article-title>Sarcomatoid carcinoma after radiation treatment of prostatic adenocarcinoma</article-title>. <source>Ann Diagn Pathol</source>. <year>2008</year>;<volume>12</volume>(<issue>2</issue>):<fpage>142</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr47-0300985811430962">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iliakis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>J</given-names>
</name>
</person-group>, et ak. <article-title>DNA damage checkpoint control in cells exposed to ionizing radiation</article-title>. <source>Oncogene</source>. <year>2003</year>;<volume>22</volume>(<issue>37</issue>):<fpage>5834</fpage>–<lpage>5847</lpage>.</citation>
</ref>
<ref id="bibr48-0300985811430962">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ittmann</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Allelic loss on chromosome 10 in prostate adenocarcinoma</article-title>. <source>Cancer Res</source>. <year>1996</year>;<volume>56</volume>(<issue>9</issue>):<fpage>2143</fpage>–<lpage>2147</lpage>.</citation>
</ref>
<ref id="bibr49-0300985811430962">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fazeli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>EM</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of an Rb mutation in the mouse</article-title>. <source>Nature</source>. <year>1992</year>;<volume>359</volume>(<issue>6393</issue>):<fpage>295</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr50-0300985811430962">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Remington</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>BO</given-names>
</name>
<etal/>
</person-group>. <article-title>Tumor spectrum analysis in p53-mutant mice</article-title>. <source>Curr Biol</source>. <year>1994</year>;<volume>4</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr51-0300985811430962">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janz</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Myc translocations in B cell and plasma cell neoplasms</article-title>. <source>DNA Repair (Amst)</source>. <year>2006</year>;<volume>5</volume>(<issue>9–10</issue>):<fpage>1213</fpage>–<lpage>1224</lpage>.</citation>
</ref>
<ref id="bibr52-0300985811430962">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jessen</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Tepper</surname>
<given-names>CG</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin</article-title>. <source>Breast Cancer Res</source>. <year>2004</year>;<volume>6</volume>(<issue>3</issue>):<fpage>R157</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr53-0300985811430962">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kayaselcuk</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tuncer</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Toyganozu</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Carcinosarcoma of the stomach</article-title>. <source>Pathol Oncol Res</source>. <year>2002</year>;<volume>8</volume>(<issue>4</issue>):<fpage>275</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr54-0300985811430962">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knudson</surname>
<given-names>AG</given-names>
<suffix> Jr</suffix>
</name>
</person-group>. <article-title>Mutation and cancer: statistical study of retinoblastoma</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1971</year>;<volume>68</volume>(<issue>4</issue>):<fpage>820</fpage>–<lpage>823</lpage>.</citation>
</ref>
<ref id="bibr55-0300985811430962">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolasa</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Rembiszewska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Janiec-Jankowska</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations</article-title>. <source>Gynecol Oncol</source>. <year>2006</year>;<volume>103</volume>(<issue>2</issue>):<fpage>692</fpage>–<lpage>697</lpage>.</citation>
</ref>
<ref id="bibr56-0300985811430962">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komiya</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer</article-title>. <source>Genes Chromosomes Cancer</source>. <year>1996</year>;<volume>17</volume>(<issue>4</issue>):<fpage>245</fpage>–<lpage>253</lpage>.</citation>
</ref>
<ref id="bibr57-0300985811430962">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korenjak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brehm</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The retinoblastoma tumour suppressor in model organisms—new insights from flies and worms</article-title>. <source>Curr Mol Med</source>. <year>2006</year>;<volume>6</volume>(<issue>7</issue>):<fpage>705</fpage>–<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr58-0300985811430962">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kunimi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bergerheim</surname>
<given-names>US</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>IL</given-names>
</name>
<etal/>
</person-group>. <article-title>Allelotyping of human prostatic adenocarcinoma</article-title>. <source>Genomics</source>. <year>1991</year>;<volume>11</volume>(<issue>3</issue>):<fpage>530</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr59-0300985811430962">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Medina</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>AA</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of p63 and basal cells in the prostate</article-title>. <source>Development</source>. <year>2004</year>;<volume>131</volume>(<issue>20</issue>):<fpage>4955</fpage>–<lpage>4964</lpage>.</citation>
</ref>
<ref id="bibr60-0300985811430962">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kusafuka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takizawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ueno</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Dedifferentiated epithelial-myoepithelial carcinoma of the parotid gland: a rare case report of immunohistochemical analysis and review of the literature</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>. <year>2008</year>;<volume>106</volume>(<issue>1</issue>):<fpage>85</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr61-0300985811430962">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lacombe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Orlow</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Reuter</surname>
<given-names>VE</given-names>
</name>
<etal/>
</person-group>. <article-title>Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer</article-title>. <source>Int J Cancer</source>. <year>1996</year>;<volume>69</volume>(<issue>2</issue>):<fpage>110</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr62-0300985811430962">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>SC</given-names>
</name>
<etal/>
</person-group>. <article-title>Phorbol 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-kappa B</article-title>. <source>J Biol Chem</source>. <year>2002</year>;<volume>277</volume>(<issue>36</issue>):<fpage>32624</fpage>–<lpage>32631</lpage>.</citation>
</ref>
<ref id="bibr63-0300985811430962">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>YK</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas</article-title>. <source>Hum Pathol</source>. <year>2007</year>;<volume>38</volume>(<issue>8</issue>):<fpage>1226</fpage>–<lpage>1231</lpage>.</citation>
</ref>
<ref id="bibr64-0300985811430962">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1998</year>;<volume>95</volume>(<issue>26</issue>):<fpage>15406</fpage>–<lpage>15411</lpage>.</citation>
</ref>
<ref id="bibr65-0300985811430962">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Lesche</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland</article-title>. <source>Development</source>. <year>2002</year>;<volume>129</volume>(<issue>17</issue>):<fpage>4159</fpage>–<lpage>4170</lpage>.</citation>
</ref>
<ref id="bibr66-0300985811430962">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liaw</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer</article-title>. <source>Science</source>. <year>1997</year>;<volume>275</volume>(<issue>5308</issue>):<fpage>1943</fpage>–<lpage>1947</lpage>.</citation>
</ref>
<ref id="bibr67-0300985811430962">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gallup</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1998</year>;<volume>95</volume>(<issue>10</issue>):<fpage>5718</fpage>–<lpage>5723</lpage>.</citation>
</ref>
<ref id="bibr68-0300985811430962">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liaw</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome</article-title>. <source>Nat Genet</source>. <year>1997</year>;<volume>16</volume>(<issue>1</issue>):<fpage>64</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr69-0300985811430962">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linzer</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells</article-title>. <source>Cell</source>. <year>1979</year>;<volume>17</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr70-0300985811430962">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>James</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Frederick</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>PTEN/MMAC1 mutations and EGFR amplification in glioblastomas</article-title>. <source>Cancer Res</source>. <year>1997</year>;<volume>57</volume>(<issue>23</issue>):<fpage>5254</fpage>–<lpage>5257</lpage>.</citation>
</ref>
<ref id="bibr71-0300985811430962">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XA</given-names>
</name>
</person-group>. <article-title>KAI1/CD82, a tumor metastasis suppressor</article-title>. <source>Cancer Lett</source>. <year>2006</year>;<volume>240</volume>(<issue>2</issue>):<fpage>183</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr72-0300985811430962">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Holstege</surname>
<given-names>H</given-names>
</name>
<name>
<surname>van der Gulden</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2007</year>;<volume>104</volume>(<issue>29</issue>):<fpage>12111</fpage>–<lpage>12116</lpage>.</citation>
</ref>
<ref id="bibr73-0300985811430962">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Magrane</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability</article-title>. <source>Mol Cell Biol</source>. <year>2001</year>;<volume>21</volume>(<issue>17</issue>):<fpage>6017</fpage>–<lpage>6030</lpage>.</citation>
</ref>
<ref id="bibr74-0300985811430962">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Solimini</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Elledge</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Principles of cancer therapy: oncogene and non-oncogene addiction</article-title>. <source>Cell</source>. <year>2009</year>;<volume>136</volume>(<issue>5</issue>):<fpage>823</fpage>–<lpage>837</lpage>.</citation>
</ref>
<ref id="bibr75-0300985811430962">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macaluso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Montanari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes</article-title>. <source>Oncogene</source>. <year>2006</year>;<volume>25</volume>(<issue>38</issue>):<fpage>5263</fpage>–<lpage>5267</lpage>.</citation>
</ref>
<ref id="bibr76-0300985811430962">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maddison</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Sutherland</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Barrios</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Conditional deletion of Rb causes early stage prostate cancer</article-title>. <source>Cancer Res</source>. <year>2004</year>;<volume>64</volume>(<issue>17</issue>):<fpage>6018</fpage>–<lpage>6025</lpage>.</citation>
</ref>
<ref id="bibr77-0300985811430962">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maehama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>JE</given-names>
</name>
</person-group>. <article-title>The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate</article-title>. <source>J Biol Chem</source>. <year>1998</year>;<volume>273</volume>(<issue>22</issue>):<fpage>13375</fpage>–<lpage>13378</lpage>.</citation>
</ref>
<ref id="bibr78-0300985811430962">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manning</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>LC</given-names>
</name>
</person-group>. <article-title>AKT/PKB signaling: navigating downstream</article-title>. <source>Cell</source>. <year>2007</year>;<volume>129</volume>(<issue>7</issue>):<fpage>1261</fpage>–<lpage>1274</lpage>.</citation>
</ref>
<ref id="bibr79-0300985811430962">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantesso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Loducca</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Jaeger</surname>
<given-names>RG</given-names>
</name>
<etal/>
</person-group>. <article-title>Analysis of epithelial-myoepithelial carcinoma based on the establishment of a novel cell line</article-title>. <source>Oral Oncol</source>. <year>2003</year>;<volume>39</volume>(<issue>5</issue>):<fpage>453</fpage>–<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr80-0300985811430962">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsh</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Dahia</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Germline mutations in PTEN are present in Bannayan-Zonana syndrome</article-title>. <source>Nat Genet</source>. <year>1997</year>;<volume>16</volume>(<issue>4</issue>):<fpage>333</fpage>–<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr81-0300985811430962">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matoso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hayama</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia</article-title>. <source>Carcinogenesis</source>. <year>2008</year>;<volume>29</volume>(<issue>3</issue>):<fpage>620</fpage>–<lpage>628</lpage>.</citation>
</ref>
<ref id="bibr82-0300985811430962">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fujii</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Arakawa</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Loss of heterozygosity analysis shows monoclonal evolution with frequent genetic progression and divergence in esophageal carcinosarcoma</article-title>. <source>Hum Pathol</source>. <year>2004</year>;<volume>35</volume>(<issue>3</issue>):<fpage>322</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr83-0300985811430962">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michael</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Oren</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The p53-Mdm2 module and the ubiquitin system</article-title>. <source>Semin Cancer Biol</source>. <year>2003</year>;<volume>13</volume>(<issue>1</issue>):<fpage>49</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr84-0300985811430962">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>HY</given-names>
</name>
<etal/>
</person-group>. <article-title>Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis</article-title>. <source>J Clin Invest</source>. <year>2007</year>;<volume>117</volume>(<issue>2</issue>):<fpage>314</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr85-0300985811430962">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moody</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Sarkisian</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>KT</given-names>
</name>
<etal/>
</person-group>. <article-title>Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis</article-title>. <source>Cancer Cell</source>. <year>2002</year>;<volume>2</volume>(<issue>6</issue>):<fpage>451</fpage>–<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr86-0300985811430962">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morris</surname><given-names>JPt</given-names></name><name><surname>Wang</surname><given-names>SC</given-names></name><name><surname>Hebrok</surname><given-names>M</given-names></name></person-group>. <article-title>KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma</article-title>. <source>Nat Rev Cancer</source>. <year>2010</year>;<volume>10</volume>(<issue>10</issue>):<fpage>683</fpage>–<lpage>695</lpage>.</citation>
</ref>
<ref id="bibr87-0300985811430962">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miyoshi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Iwao</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Combined hepatocellular/cholangiocellular carcinoma with sarcomatoid features: genetic analysis for histogenesis</article-title>. <source>Hepatol Res</source>. <year>2001</year>;<volume>21</volume>(<issue>3</issue>):<fpage>220</fpage>–<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr88-0300985811430962">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagao</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sugano</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Salivary gland malignant myoepithelioma: a clinicopathologic and immunohistochemical study of ten cases</article-title>. <source>Cancer</source>. <year>1998</year>;<volume>83</volume>(<issue>7</issue>):<fpage>1292</fpage>–<lpage>1299</lpage>.</citation>
</ref>
<ref id="bibr89-0300985811430962">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagao</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sugano</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Hybrid carcinomas of the salivary glands: report of nine cases with a clinicopathologic, immunohistochemical, and p53 gene alteration analysis</article-title>. <source>Mod Pathol</source>. <year>2002</year>;<volume>15</volume>(<issue>7</issue>):<fpage>724</fpage>–<lpage>733</lpage>.</citation>
</ref>
<ref id="bibr90-0300985811430962">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakayama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shirane</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors</article-title>. <source>Cell</source>. <year>1996</year>;<volume>85</volume>(<issue>5</issue>):<fpage>707</fpage>–<lpage>720</lpage>.</citation>
</ref>
<ref id="bibr91-0300985811430962">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelen</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>van Staveren</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Peeters</surname>
<given-names>EA</given-names>
</name>
<etal/>
</person-group>. <article-title>Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease</article-title>. <source>Hum Mol Genet</source>. <year>1997</year>;<volume>6</volume>(<issue>8</issue>):<fpage>1383</fpage>–<lpage>1387</lpage>.</citation>
</ref>
<ref id="bibr92-0300985811430962">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niida</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>DNA damage checkpoints in mammals</article-title>. <source>Mutagenesis</source>. <year>2006</year>;<volume>21</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr93-0300985811430962">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nikitin</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Juarez-Perez</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/– mice</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1999</year>;<volume>96</volume>(<issue>7</issue>):<fpage>3916</fpage>–<lpage>3921</lpage>.</citation>
</ref>
<ref id="bibr94-0300985811430962">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nakatsuru</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas</article-title>. <source>Cancer Res</source>. <year>1995</year>;<volume>55</volume>(<issue>3</issue>):<fpage>658</fpage>–<lpage>662</lpage>.</citation>
</ref>
<ref id="bibr95-0300985811430962">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nishida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Miyauchi</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Dedifferentiated malignant myoepithelioma of the parotid gland</article-title>. <source>Pathol Int</source>. <year>2003</year>;<volume>53</volume>(<issue>10</issue>):<fpage>704</fpage>–<lpage>709</lpage>.</citation>
</ref>
<ref id="bibr96-0300985811430962">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pesche</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Latil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muzeau</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>PTEN/MMAC1/TEP1 involvement in primary prostate cancers</article-title>. <source>Oncogene</source>. <year>1998</year>;<volume>16</volume>(<issue>22</issue>):<fpage>2879</fpage>–<lpage>2883</lpage>.</citation>
</ref>
<ref id="bibr97-0300985811430962">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petitjean</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mathe</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database</article-title>. <source>Hum Mutat</source>. <year>2007</year>;<volume>28</volume>(<issue>6</issue>):<fpage>622</fpage>–<lpage>629</lpage>.</citation>
</ref>
<ref id="bibr98-0300985811430962">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Morton</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer</article-title>. <source>Br J Urol</source>. <year>1994</year>;<volume>73</volume>(<issue>4</issue>):<fpage>390</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr99-0300985811430962">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Planas-Silva</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>The restriction point and control of cell proliferation</article-title>. <source>Curr Opin Cell Biol</source>. <year>1997</year>;<volume>9</volume>(<issue>6</issue>):<fpage>768</fpage>–<lpage>772</lpage>.</citation>
</ref>
<ref id="bibr100-0300985811430962">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Podsypanina</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ellenson</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Nemes</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1999</year>;<volume>96</volume>(<issue>4</issue>):<fpage>1563</fpage>–<lpage>1568</lpage>.</citation>
</ref>
<ref id="bibr101-0300985811430962">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popnikolov</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Ayala</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Graves</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas</article-title>. <source>Am J Clin Pathol</source>. <year>2003</year>;<volume>120</volume>(<issue>2</issue>):<fpage>161</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr102-0300985811430962">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prives</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>PA</given-names>
</name>
</person-group>. <article-title>The p53 pathway</article-title>. <source>J Pathol</source>. <year>1999</year>;<volume>187</volume>(<issue>1</issue>):<fpage>112</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr103-0300985811430962">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raimondi</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Vitale-Cross</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Amornphimoltham</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Rapid development of salivary gland carcinomas upon conditional expression of K-ras driven by the cytokeratin 5 promoter</article-title>. <source>Am J Pathol</source>. <year>2006</year>;<volume>168</volume>(<issue>5</issue>):<fpage>1654</fpage>–<lpage>1665</lpage>.</citation>
</ref>
<ref id="bibr104-0300985811430962">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rakha</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>El-Sheikh</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Kandil</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Expression of BRCA1 protein in breast cancer and its prognostic significance</article-title>. <source>Hum Pathol</source>. <year>2008</year>;<volume>39</volume>(<issue>6</issue>):<fpage>857</fpage>–<lpage>865</lpage>.</citation>
</ref>
<ref id="bibr105-0300985811430962">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rice</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Uddemarri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Desai</surname>
<given-names>DH</given-names>
</name>
<etal/>
</person-group>. <article-title>PGF2alpha-associated vascular smooth muscle hypertrophy is ROS dependent and involves the activation of mTOR, p70S6k, and PTEN</article-title>. <source>Prostaglandins Other Lipid Mediat</source>. <year>2008</year>;<volume>85</volume>(<issue>1–2</issue>):<fpage>49</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr106-0300985811430962">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Risinger</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Berchuck</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>PTEN/MMAC1 mutations in endometrial cancers</article-title>. <source>Cancer Res</source>. <year>1997</year>;<volume>57</volume>(<issue>21</issue>):<fpage>4736</fpage>–<lpage>4738</lpage>.</citation>
</ref>
<ref id="bibr107-0300985811430962">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robanus-Maandag</surname>
<given-names>E</given-names>
</name>
</person-group>, <article-title>Dekker M, van der Valk M, et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice</article-title>. <source>Genes Dev</source>. <year>1998</year>;<volume>12</volume>(<issue>11</issue>):<fpage>1599</fpage>–<lpage>1609</lpage>.</citation>
</ref>
<ref id="bibr108-0300985811430962">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>AR</given-names>
</name>
</person-group>. <article-title>Cowden disease and Lhermitte-Duclos disease: an update. Case report and review of the literature</article-title>. <source>Neurosurg Focus</source>. <year>2006</year>;<volume>20</volume>(<issue>1</issue>):<fpage>E6</fpage>.</citation>
</ref>
<ref id="bibr109-0300985811430962">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Pinilla</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Rodriguez-Gil</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Moreno-Bueno</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study</article-title>. <source>Am J Surg Pathol</source>. <year>2007</year>;<volume>31</volume>(<issue>4</issue>):<fpage>501</fpage>–<lpage>508</lpage>.</citation>
</ref>
<ref id="bibr110-0300985811430962">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miyoshi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Landesman-Bollag</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors</article-title>. <source>Am J Pathol</source>. <year>2002</year>;<volume>161</volume>(<issue>3</issue>):<fpage>1087</fpage>–<lpage>1097</lpage>.</citation>
</ref>
<ref id="bibr111-0300985811430962">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saal</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Holm</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2007</year>;<volume>104</volume>(<issue>18</issue>):<fpage>7564</fpage>–<lpage>7569</lpage>.</citation>
</ref>
<ref id="bibr112-0300985811430962">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saenz Robles</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Symonds</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Induction versus progression of brain tumor development: differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen</article-title>. <source>Mol Cell Biol</source>. <year>1994</year>;<volume>14</volume>(<issue>4</issue>):<fpage>2686</fpage>–<lpage>2698</lpage>.</citation>
</ref>
<ref id="bibr113-0300985811430962">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salmena</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Carracedo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>PP</given-names>
</name>
</person-group>. <article-title>Tenets of PTEN tumor suppression</article-title>. <source>Cell</source>. <year>2008</year>;<volume>133</volume>(<issue>3</issue>):<fpage>403</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr114-0300985811430962">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scherl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Cardiff</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group>. <article-title>Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice</article-title>. <source>Prostate</source>. <year>2004</year>;<volume>59</volume>(<issue>4</issue>):<fpage>448</fpage>–<lpage>459</lpage>.</citation>
</ref>
<ref id="bibr115-0300985811430962">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shappell</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>RL</given-names>
</name>
<etal/>
</person-group>. <article-title>Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee</article-title>. <source>Cancer Res</source>. <year>2004</year>;<volume>64</volume>(<issue>6</issue>):<fpage>2270</fpage>–<lpage>2305</lpage>.</citation>
</ref>
<ref id="bibr116-0300985811430962">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sherr</surname>
<given-names>CJ</given-names>
</name>
</person-group>. <article-title>Principles of tumor suppression</article-title>. <source>Cell</source>. <year>2004</year>;<volume>116</volume>(<issue>2</issue>):<fpage>235</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr117-0300985811430962">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiota</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Onitsuka</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Twist and p53 reciprocally regulate target genes via direct interaction</article-title>. <source>Oncogene</source>. <year>2008</year>;<volume>27</volume>(<issue>42</issue>):<fpage>5543</fpage>–<lpage>5553</lpage>.</citation>
</ref>
<ref id="bibr118-0300985811430962">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stambolic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Tsao</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Macpherson</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/– mice</article-title>. <source>Cancer Res</source>. <year>2000</year>;<volume>60</volume>(<issue>13</issue>):<fpage>3605</fpage>–<lpage>3611</lpage>.</citation>
</ref>
<ref id="bibr119-0300985811430962">
<label>119</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steck</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Pershouse</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Jasser</surname>
<given-names>SA</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers</article-title>. <source>Nat Genet</source>. <year>1997</year>;<volume>15</volume>(<issue>4</issue>):<fpage>356</fpage>–<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr120-0300985811430962">
<label>120</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steeg</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Ouatas</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Halverson</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Metastasis suppressor genes: basic biology and potential clinical use</article-title>. <source>Clin Breast Cancer</source>. <year>2003</year>;<volume>4</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr121-0300985811430962">
<label>121</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stiles</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Groszer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>PTENless means more</article-title>. <source>Dev Biol</source>. <year>2004</year>;<volume>273</volume>(<issue>2</issue>):<fpage>175</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr122-0300985811430962">
<label>122</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Freije</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nusskern</surname>
<given-names>DR</given-names>
</name>
<etal/>
</person-group>. <article-title>Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues</article-title>. <source>Cancer Res</source>. <year>1998</year>;<volume>58</volume>(<issue>2</issue>):<fpage>204</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr123-0300985811430962">
<label>123</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Symonds</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Krall</surname>
<given-names>L</given-names>
</name>
</person-group>, <article-title>Remington L, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo</article-title>. <source>Cell</source>. <year>1994</year>;<volume>78</volume>(<issue>4</issue>):<fpage>703</fpage>–<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr124-0300985811430962">
<label>124</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szukala</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Burchette</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases</article-title>. <source>Int J Gynecol Cancer</source>. <year>1999</year>;<volume>9</volume>(<issue>2</issue>):<fpage>131</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr125-0300985811430962">
<label>125</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Zighelboim</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Huettner</surname>
<given-names>PC</given-names>
</name>
<etal/>
</person-group>. <article-title>DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis</article-title>. <source>Mod Pathol</source>. <year>2006</year>;<volume>19</volume>(<issue>10</issue>):<fpage>1333</fpage>–<lpage>1338</lpage>.</citation>
</ref>
<ref id="bibr126-0300985811430962">
<label>126</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teng</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines</article-title>. <source>Cancer Res</source>. <year>1997</year>;<volume>57</volume>(<issue>23</issue>):<fpage>5221</fpage>–<lpage>5225</lpage>.</citation>
</ref>
<ref id="bibr127-0300985811430962">
<label>127</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trybus</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Wojno</surname>
<given-names>KJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer</article-title>. <source>Cancer Res</source>. <year>1996</year>;<volume>56</volume>(<issue>10</issue>):<fpage>2263</fpage>–<lpage>2267</lpage>.</citation>
</ref>
<ref id="bibr128-0300985811430962">
<label>128</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ursini-Siegel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schade</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cardiff</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group>. <article-title>Insights from transgenic mouse models of ERBB2-induced breast cancer</article-title>. <source>Nat Rev Cancer</source>. <year>2007</year>;<volume>7</volume>(<issue>5</issue>):<fpage>389</fpage>–<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr129-0300985811430962">
<label>129</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Nederveen</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Perren</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dannenberg</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas</article-title>. <source>J Pathol</source>. <year>2006</year>;<volume>209</volume>(<issue>2</issue>):<fpage>274</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr130-0300985811430962">
<label>130</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ventura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kirsch</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>ME</given-names>
</name>
<etal/>
</person-group>. <article-title>Restoration of p53 function leads to tumour regression in vivo</article-title>. <source>Nature</source>. <year>2007</year>;<volume>445</volume>(<issue>7128</issue>):<fpage>661</fpage>–<lpage>665</lpage>.</citation>
</ref>
<ref id="bibr131-0300985811430962">
<label>131</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogelstein</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Surfing the p53 network</article-title>. <source>Nature</source>. <year>2000</year>;<volume>408</volume>(<issue>6810</issue>):<fpage>307</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr132-0300985811430962">
<label>132</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vooijs</surname>
<given-names>M</given-names>
</name>
<name>
<surname>te Riele</surname>
<given-names>H</given-names>
</name>
<name>
<surname>van der Valk</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding protein-expressing cells</article-title>. <source>Oncogene</source>. <year>2002</year>;<volume>21</volume>(<issue>30</issue>):<fpage>4635</fpage>–<lpage>4645</lpage>.</citation>
</ref>
<ref id="bibr133-0300985811430962">
<label>133</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinberg</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>The retinoblastoma protein and cell cycle control</article-title>. <source>Cell</source>. <year>1995</year>;<volume>81</volume>(<issue>3</issue>):<fpage>323</fpage>–<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr134-0300985811430962">
<label>134</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinstein</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Begemann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy</article-title>. <source>Clin Cancer Res</source>. <year>1997</year>;<volume>3</volume>(<issue>12, pt 2</issue>):<fpage>2696</fpage>–<lpage>2702</lpage>.</citation>
</ref>
<ref id="bibr135-0300985811430962">
<label>135</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wikenheiser-Brokamp</surname>
<given-names>KA</given-names>
</name>
</person-group>. <article-title>Rb family proteins differentially regulate distinct cell lineages during epithelial development</article-title>. <source>Development</source>. <year>2004</year>;<volume>131</volume>(<issue>17</issue>):<fpage>4299</fpage>–<lpage>4310</lpage>.</citation>
</ref>
<ref id="bibr136-0300985811430962">
<label>136</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Remington</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences</article-title>. <source>EMBO J</source>. <year>1994</year>;<volume>13</volume>(<issue>18</issue>):<fpage>4251</fpage>–<lpage>4259</lpage>.</citation>
</ref>
<ref id="bibr137-0300985811430962">
<label>137</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>XR</given-names>
</name>
</person-group>. <article-title>Urothelial tumorigenesis: a tale of divergent pathways</article-title>. <source>Nat Rev Cancer</source>. <year>2005</year>;<volume>5</volume>(<issue>9</issue>):<fpage>713</fpage>–<lpage>725</lpage>.</citation>
</ref>
<ref id="bibr138-0300985811430962">
<label>138</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zender</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Miething</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas</article-title>. <source>Nature</source>. <year>2007</year>;<volume>445</volume>(<issue>7128</issue>):<fpage>656</fpage>–<lpage>660</lpage>.</citation>
</ref>
<ref id="bibr139-0300985811430962">
<label>139</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ohnami</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Development of gene therapy to target pancreatic cancer</article-title>. <source>Cancer Sci</source>. <year>2004</year>;<volume>95</volume>(<issue>4</issue>):<fpage>283</fpage>–<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr140-0300985811430962">
<label>140</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Longmore</surname>
<given-names>GD</given-names>
</name>
</person-group>. <article-title>Differential regulation of apoptotic genes by Rb in human versus mouse cells</article-title>. <source>Oncogene</source>. <year>2004</year>;<volume>23</volume>(<issue>15</issue>):<fpage>2587</fpage>–<lpage>2599</lpage>.</citation>
</ref>
<ref id="bibr141-0300985811430962">
<label>141</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>TZ</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo</article-title>. <source>Endocrinology</source>. <year>2000</year>;<volume>141</volume>(<issue>12</issue>):<fpage>4698</fpage>–<lpage>4710</lpage>.</citation>
</ref>
<ref id="bibr142-0300985811430962">
<label>142</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>ZT</given-names>
</name>
<name>
<surname>Pak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma</article-title>. <source>Cancer Res</source>. <year>1999</year>;<volume>59</volume>(<issue>14</issue>):<fpage>3512</fpage>–<lpage>3517</lpage>.</citation>
</ref>
<ref id="bibr143-0300985811430962">
<label>143</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Morse</surname>
<given-names>HC III</given-names>
</name>
<etal/>
</person-group>. <article-title>Deregulated expression of the Myc cellular oncogene drives development of mouse “Burkitt-like” lymphomas from naive B cells</article-title>. <source>Blood</source>. <year>2005</year>;<volume>105</volume>(<issue>5</issue>):<fpage>2135</fpage>–<lpage>2137</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>